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Immunotherapy as a means for cancer treatment has been investigated for over a 
century.  While studies have been completed using different immunological strategies, 
development of a clinical therapeutic cancer vaccine has proven elusive.  Recently, 
success has been seen with prophylactic vaccines for cancers with known viral origins 
(Gardasil® and Cervarix for Human Papiloma Virus).  However, such strategies do not 
address the challenge in generating effective immune response against other tumor 
antigens, most of which are weakly immunogenic self-antigens.  Tolerance to these self-
antigens could ultimately limit the patient’s ability to mount an effective anti-tumor 
immune response.   
The US Food and Drug Administration recently approved the first DC cell-based 
cancer vaccine, Provenge®, for use in prostate cancer.  This vaccine requires cell 
isolations from the patient as well as in vitro DC modifications, which ultimately leads to 
high cost as well as multiple procedures.  However, results indicate that, on average, 
patients live only four months longer than those receiving a placebo.  While this work 
remains important, and offers proof that priming DCs can improve the lifespan of a 
patient, it ultimately does not offer a long-term cure.  Direct and highly efficient in vivo 
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delivery of antigens to DCs could overcome the challenges associated with ex vivo DC 
manipulation and may offer a more scalable method for generating anti-tumor immunity.   
This research focuses on the development of novel formulations that allow 
simultaneous delivery of protein/peptide-based tumor antigens and immune-modulatory 
nucleic acids (siRNA and immune stimulatory CpG) to the same dendritic cells (DCs) in-
vivo.  Such formulations allow a synthetic immune-priming center to be created at the site 
of immunization and simultaneously deliver the tumor antigen to DCs and modulate their 
immune response through IL-10 silencing.  Our hypothesis is that using such a DC-
targeted dual delivery system we will be able to illicit strong T helper 1 (TH1) and 
Cytotxic T Lymphocyte (CTL) response in vivo against a wide array of tumor antigens.  
This can become a platform technology where the biomolecules (antigen and 
immunomodulatory agents) can be easily varied based on particular cancers. 
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Introduction:  Specific Aims and Overview 
1.1 INTRODUCTION: 
Immunotherapy as applied to infectious disease is considered to be the most cost-
effective and safe method for the control of many diseases.  Immunization has had a 
tremendous impact on health worldwide, as demonstrated by the global eradication of 
smallpox:  there has not been a single reported case since 1977, however, new 
immunization strategies need to be employed in order to generate effective immune 
responses to chronic viral or tumor antigens, most of which are self-antigens (Friede and 
Aguado, 2005).  While many of the most potent vaccines on today’s market are given as 
a live attenuated or a killed form of the microorganism, many potential drawbacks exist 
for both of these strategies. These include poor efficacy of boosting antibody responses 
and safety concerns.  For example, the pertussis attenuated bacterial vaccine has been 
shown to cause seizures, encephalitis, brain damage, and even death.  By applying recent 
immunological findings such as new information about the cells of the immune system 
and the microenvironments within which these cells reside to vaccine development, it 
may be possible to create a safer, more cost effective vaccination platform capable of 
eliciting the appropriate immune  response specific for the disease (Hubbell et al., 2009). 
My thesis work is focused on doing that by applying a biomaterial-based approach to 
create a protein-based vaccine delivery platform capable of generating both an antigen 
specific immune response as well as one that is T helper (TH) 1 specific and capable of 
eliciting a cytotoxic T-cell (CTL) response (Kasturi et al., 2005; Singh et al., 2008, 2009).  
Previously, our laboratory has completed work on creating a biomaterial-based dendritic 
cell priming center in order to attract immature DCs to the location of microparticle 
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administration in order to more effectively target DCs for transfection using a DNA 
based vaccine (Singh et al., 2009).  Although our results indicate that this is a promising 
new immunization option, the overall potency of DNA vaccines in human trials is low 
and can be attributed to low efficiency of DNA transfection to translation into antigenic 
proteins.  This is further affected by inefficient presentation of translated proteins on 
surface of antigen presenting cells.  Here we hypothesize that by delivering the actual 
protein antigen peptide (by-passing the need for cellular transfection) we will be able to 
induce TH1 specific responses to our antigenic protein more effectively. 
Most viral formulations function by targeting antigen presenting cells (APCs) 
such as B cells, macrophages and dendritic cells (DCs), which are known to be the most 
prominent T-cell activators. Although dendritic cells have the potential to act as a cellular 
vaccine, clinical trials of ex-vivo major histocompatibility complex (MHC) primed DCs 
have shown a lack of persistent expression of MHC Class I complexes on their surface. 
These complexes only remain on the surface on the order of a few hours making long 
term immunity using these methods improbable.  These procedures would also require 
cell isolations as well as in vitro DC modifications, which would ultimately lead to high 
cost as well as additional procedures for the patient. Additionally, and more importantly, 
90% of these transplanted DCs die and very few of the surviving cells actually migrate to 
the lymph node (Ali et al., 2009).  Therefore, in vivo protein delivery to DCs would be 
preferential.  Bolus injections of proteins are, however, considerably less immunogenic 
when administered alone and are frequently subject to degradation and clearance from the 
body.  One way to enhance protein uptake by APCs is by delivering them via particulate 
systems.  Because particulate delivery systems are more comparable in size to common 
pathogens (~ 1 um) APCs have been shown to preferentially uptake these particles and 
therefore the particle associated proteins as well.  This enhanced uptake by APCs is an 
 3 
important contributing factor in the ability of these delivery systems to induce more 
potent immune responses than soluble antigens.  Additionally, by using a particulate 
system, it would be possible to ensure delivery of more than just a single protein 
molecule as well as combine delivery with an adjuvant or other immunomodulatory 
molecules (Singh et al., 2008, 2004a; Vajdy et al., 2004).   
An imbalance between the TH1 and TH2 response has been implicated in several 
chronic infectious diseases such as human immunodeficiency virus infection and chronic 
hepatitis B and C infections.  Mature T helper cells, also referred to as CD4+ T cells, are 
central to the induction of anti-viral responses, have been subdivided according to two 
predominant cytokine secretion profiles.  TH1 cells produce cytokines such as interleukin 
(IL)-2, interferon-gamma (IFN-γ), and tumor necrosis factor beta which are important 
factors responsible for promoting the cell-mediated immune response. TH2 cells produce 
cytokines such as IL-4, IL-5 and IL-10 which mediate the humoral, or antibody mediated 
response. Cytokines released by one type of TH lymphocyte population can down-
regulate the functions of the other TH population subset.  Furthermore, it has been 
suggested that the initial development of APCs into TH1 or TH2 phenotype is believed to 
depend on the leading cytokines at the site of initial antigen presentation, the type of 
antigen presenting cell, the nature of the co-stimulatory molecules involved, and the dose 
of stimulatory antigens.  This phenotypic commitment may be critical for the subsequent 
differentiation of immune cells nonspecifically recruited at the site of infection 
(Thompson, 1995). 
The main objective of this research project is to overcome the barriers in current 
vaccine formulations by: a) carefully investigating different surface modification 
techniques to impart anionic or cationic charges to poly(lactic-co-glycolic acid) (PLGA) 
microparticles, b) systematically altering protein loading conditions to ensure optimal 
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protein dosage to DCs, and c) co-delivery of protein antigens as well as 
immunomodulatory molecules such as siRNA to ensure optimal CTL response.  We 
hypothesize that using this microparticle formulation we will be able to illicit a CTL 
response in vivo capable of combating chronic viral diseases such as Hepatitis B and 
cancer.   
1.2 SPECIFIC AIMS: 
1.2.1 Aim 1: Optimize and characterize biodegradable, surface-functionalized, 
polymer microparticles for loading of proteins for the delivery to antigen presenting 
cells.    
We hypothesize that we can impart a significant amount of cationic or anionic 
charge on our PLGA microparticles and that we will be able to use that charge to adsorb 
proteins onto the surface of the charged microparticles.  The cationic charge will be 
achieved by functionalizing our microparticles with branched PEI as previously described 
(Kasturi et al., 2005; Singh et al., 2008, 2009).  An anioinic charge will be imparted on 
our microparticles by exposing the particles to either helium or oxygen plasma using both 
low pressure plasma systems as well as an atmospheric plasma system developed by Dr. 
Raja in the Department of Mechanical Engineering at the University of Texas at Austin 
(Shin and Raja, 2003).  Charge modification will be confirmed using zeta potential 
analysis.  In the case of plasma treated microparticles, optimized protein loading 
condition experiments will be of the utmost importance as plasma surface modification 
may also increase several other factors altering protein adsorption most importantly:  
hydrophobicity and surface roughness (Fortunati et al., 2013; Shen et al., 2008).  Once 
surface properties are analyzed we will adsorb protein electrostatically to the surface of 
these particles.  This will be done by utilizing the protein’s isoelectric point by varying 
key parameters to drive favorable electrostatic interactions to obtain high surface loading 
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of proteins, these parameters include:  pH, ionic strength, and type of buffer.  An 
overview of the project can be seen in Figure 1.1. 
 
1.2.2 Aim 2:  Optimize particle formulation for maximum co-delivery of 
immunomodulatory molecules.   
Because proteins are weakly immunogenic on their own, and tolerance to our 
protein antigen is of the utmost concern, we will include in the formulation process an 
immunomudulatory molecule to enhance the immune response.  We hypothesize that by 
utilizing electrostatic interactions we can drive protein attachment in combination with 
immunomudulatory molecule attachment in order to be able to deliver multiple types of 
molecules on a single particle.  We will then evaluate the efficiency of our co-delivery 
system as compared to single loaded particle controls in activating DCs in vitro in order 
to mount an immune reaction.  This will be done by first, looking at DC cellular 
activation markers using flow cytometry.  We will then further study our particles ability 
to activate DCs by looking at both cytokine release as well as altered gene expression.  
Using these in vitro characterization methods we will choose appropriate particulate 
systems to move forward with for in vivo studies.  
 
1.2.3 Aim 3:  Test our optimized system from Aim 2 in an in vivo tumor model.   
We hypothesize that our in vitro characterized molecules will be able to effectively limit 
tumor growth in an in vivo model.  This will be done using an ovalbumin expressing 
melanoma cell model, murine B16 cells that were generously provided by Dr. Zhengrong 
Cui.  We will test our formulations in both a prophylactic and therapeutic model 
monitoring tumor growth and survival.  This will be done according to protocols 
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approved by the University of Texas at Austin Institutional Animal Care and Use 




Chapter 2 will focus on the background and significance of this thesis work 
focusing on the latest research in immunotherapy based fields.  The following chapter, 
Chapter 3 will focus on plasma surface functionalization of the PLGA microparticles 
and protein loading.  It will describe the characterization in terms of surface charge, 
morphology, and the ability to adsorb protein to the surface of these particles.  Chapter 4 
will discuss the characterization techniques of the PEI functionalized microparticles.  
Again, characterization will be discussed in terms of charge and ability to adsorb protein 
and immunomodulatory molecules to the surface.  Chapter 5 will focus on in vitro and in 
vivo studies to determine the most effective vaccine formulations developed in Chapter 
4.  In vitro characterization will be done using flow cytometry surface analysis of DC 
activation, cytokine secretion, and gene expression.  In vivo studies were completed 
performing both a therapeutic and prophylactic model.  Chapter 6 will conclude the 
dissertation and discuss possible future recommendations and applications of the vaccine 
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Background and Significance  
2.1 IMMUNIZATION AND DENDRITIC CELL FUNCTION OVERVIEW 
Protein antigens offer promising new treatments to diseases for which there are no 
current vaccines available or ones where immunity resulting from infection may not be 
ideal or possible in the case of cancer.  Recently more than 170 antigenic peptides from 
60 human tumor antigens have been discovered (van der Bruggen et al., 2013).  
Synthetically derived peptide sequences offer the opportunity to design a particular 
epitope that can be used in vaccines to mount a specific and desirable immune response 
(Arnon and Horwitz, 1992; Ben-Yedidia and Arnon, 1997).  Although protein based 
vaccines are considered to be safer than traditional viral formulations (a list of current 
protein based vaccines can be found in Table 2.1) in that they are chemically defined and 
do not contain any potentially infectious materials, they are considerably less 
immunogenic when administered alone and are frequently subject to degradation and 
clearance from the body (Bharali et al., 2008).  Therefore, most protein vaccine 
development strategies work on targeting specific immune cells and actively 
manipulating the complicated DC response in order to generate a desired immune 
response as reviewed by Hubbell et al. (Hubbell et al., 2009).  Because protein based 
vaccines are non-immunogenic in order for them to be affective the proteins need to be 
administered in combination with another immune-stimulating material, this can be an 
immune adjuvant or an immune-stimulating delivery system (Leleux and Roy, 2013a). 
Briefly, immature DCs take up antigens from the extracellular fluid, process them 
and present them on class II major histocompatibility complex (MHC) molecules.  CD4+ 
T cells can recognize the antigen alone or with co-stimulatory molecules (these include 
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CD80/B7.1 and CD86/B7.2) depending on the activation state.  If the protein is 
endogenously made, the DC will process the protein via a separate pathway and present 
them via class I MHC molecules, which interact with CD8+ T cells.  Assuming they do 
not encounter a secondary pathogenic molecule, or adjuvant, they will continue to remain 
in the immature phenotype.  DCs maturation can be induced by a variety of different 
signals including:  pathogen-associated molecular patterns (such as LPS), bacterial DNA, 
double-stranded RNA, and T cell-derived signals (Banchereau et al., 2000).  One of the 
main mechanisms that DCs use to recognize pathogenic microorganisms is the Toll-like 
receptors (TLRs) which can recognize specific molecular patterns present on a microbe, 
also known as pathogen-associated molecular patterns (PAMPs) (as reviewed in (Akira 
and Takeda, 2004)).  The differences in DC function after maturation are illustrated in 
Figure 2.1.  Only mature, activated DCs will migrate to draining lymph vessels to the 
nearest lymph node, while immature DCs will continue to circulate through the 
peripheral tissues systemically. Further, activated DCs present MHC-peptide complexes 
for days to ensure T cell interaction, whereas immature DC expression of MHC 
molecules is more transient (Cella et al., 1997; Pierre et al., 1997).  If DCs do not achieve 
the necessary secondary activation or if weak antigens or low antigen concentrations are 
presented to the DCs, the DC may remain in a semi-mature state and induce 
immunotolerance against the presented antigen (Aichele et al., 1995; Mahnke et al., 2002; 
Rutella et al., 2006).  Mature DCs are capable of presenting both the antigen and co-
stimulatory molecules capable of activating T cells.  
 The type of immune response initiated at this point is dependent on a number of 
factors, first and foremost is the type of MHC molecule which the antigen is presented on 
(as mentioned previously).  Another contributing factor is the cytokines present in the 
extracellular environment. These molecules can induce either a TH1 or TH2 specific 
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response in CD4+ T cells (as reviewed in (Banchereau and Steinman, 1998; Pulendran et 
al., 2001).  By actively controlling this microenvironment it may be possible to drive the 
immune response, as demonstrated by Singh et al., using short interfering RNA (siRNA) 
to silence the expression of IL-10 in order to generate a TH1 type immune response (Park 
et al., 2013; Sato et al., 1999; Singh et al., 2008).  In this way, by silencing expression of 
IL-10 on the dendritic cell level, Singh was able to show that this was enough to drive the 
type of immune response desired without having to manipulate multiple cell populations.  
By combining new recent findings in immunology along with the basic concept of a 
protein based vaccine, it may be possible to preferentially drive the immune system to 
create a desired response. 
 
2.2 PROTEIN VACCINES AND USE OF ADJUVANTS 
 In principle, the simplest vaccine capable of targeting the adaptive immune 
system would consist of a short peptide encompassing MHC class I-restricted epitopes.  
However, the use of soluble peptides as vaccines alone has not been successful.  While 
the exact reasons for the poor immunogenicity are not well understood, some studies in 
mice have demonstrated that, instead of activating T cells, soluble peptides tolerize 
and/or delete antigen specific T cells (Aichele et al., 1995; Enk et al., 1997; Lutz and 
Schuler, 2002).  A number of strategies have been developed to overcome the weakness 
of peptides in creating an immune response, specifically usage of adjuvants, lipopeptide 
conjugation, and direct delivery of peptides to DCs have become popular approaches in 
developing an immune response (Purcell et al., 2007).  Additionally, groups have begun 
actually modifying the protein peptide to aid in their immunogenicity.  One strategy 
involves chemically modifying the peptide to improve the way that it binds to the MHC 
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(Cole et al., 2010).  Another strategy of this kind involves increasing the strength of the 
interaction between the epitope and the T cell receptor (Sette and Fikes, 2003).  These 
strategies are not, however, without their complications.  Data suggests that while the 
avidity of the peptide is stronger, using these altered peptides can actually affect the T 
cell specificity to the intended target cells and, ultimately, each chemically modified 
epitope needs to be more carefully evaluated to ensure its’ specificity to the proteins in 
question (Cole et al., 2010).   
The usage of adjuvants has, therefore, become common.  Advances in basic 
immunology knowledge about how innate immune signals can shape adaptive responses 
along with improvements in biochemical techniques have led to the design of better 
adjuvants. Alum, the most commonly used vaccine adjuvant has been in use for the past 
80 years (Kool et al., 2011).  It is made up of aluminium potassium sulfate and has been 
shown to induce stronger antibody production.  Currently is can be found in several 
vaccines on the market including:  DTP (Diptheria-Tetanus-Pertussis combination), 
Pediarix (DTP-HBV-Polio combination), Pentacel (DTP-Haemophilus influenza B 
(HIB)-Polio combination), Hepatitis A, HBV, HPV, HIB, and pneumococcal vaccines 
(Kool et al., 2011).  Pediarix currently in use in the hepatitis B vaccine, which is 
comprised of the recombinant surface antigen for hepatitis B (HBsAg) adsorbed to alum, 
the adjuvant.  However, safety concerns for alum and other adjuvants have been 
expressed due to reports of side effects, such as nodule formation, local toxicity and 
inflammation (Trollfors et al., 2005).  Additionally, alum based adjuvants induce only a 
TH2 specific response and is therefore ultimately limited in its applications.  Of note, the 
exact mechanisms that result in the adjuvantcy of alum remains largely elusive (as 
reviewed in (Kool et al., 2011)) and discovering the exact mechanism of action that alum 
has on DCs may help to improve overall adjuvanticity of alum. 
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MF59 is a squalene-based oil-in-water emulsion formulation that also has been 
licensed for human use.  In trials for a bird flu vaccine, MF59 was shown to induce 
antibody responses comparable to levels indicative of protection whereas soluble antigen 
failed to elicit any response (Nicholson et al., 2001).  The only negative side effects 
reported were complaints of pain at injection sights where most were of short duration 
(Nicholson et al., 2001).  Mechanistically, it has been shown that MF59 is a more potent 
activator of immune related genes than alum and CpG (Mosca et al., 2008).  This 
suggests that in addition to delivering the antigen that MF59 also induces a strong 
immune-stimulating response directly at the site of injection by inducing the production 
of immune mediators and triggering the recruitment of CD11b+ monocytes (Mosca et al., 
2008) in this way acting as a multi-functional vaccine adjuvant. 
Incomplete Freund’s Adjuvant, another well researched adjuvant, was changed in 
2006 as a result of concerns about prion contamination, changing the formula from beef-
derived to an olive-derived one  While the olive-derived IFA is better tolerated in human 
trials (the beef derived IFA actually was shown to cause severe local skin reactions) it 
also failed to produce the same immunization seen in the beef derived IFA (Rosenberg et 
al., 2010).   
One possible way to cause an immune response is to use our existing knowledge 
of TLR agonists to exploit the signaling pathways that DCs use to design a synthetic 
ligand that can target the TLRs more safely than a pathogen-derived ligand.  One popular 
agonist researched is CpG (Davis et al., 1998; Hartmann et al., 1999; Klinman et al., 
1999; Krieg, 2002).  Unmethylated CpG DNA is a known TLR9 agonist because most of 
the mammalian geneome is methylated but bacteria lack CpG methylation enzymes, 
thereby creating a PAMP.  CpG, as used in the terms of an adjuvant, refers to 
unemethylated cytidine-guanosine dinucleotides within a specific pattern of flanking 
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bases.  Dendritic cells naturally recognize this material and associate it with being in the 
presence of bacterial DNA.  CpG has been shown to induce stronger systemic responses 
(i.e. more widespread responses as compared to MF59’s responses which tend to be more 
local) compared with MF59 and alum (Mosca et al., 2008).  Of note, there exists a 
species-specific difference in the optimal CpG motif for activation (Lipford et al., 1997).  
There exists many more TLRs both on the surface of dendritic cells as well as on their 
endosomes (Table 2.2).  Their location correlates with the type of molecule that it acts to 
recognize.  These may present further potential for future adjuvant design.  Further, the 
delivery system used for protein/adjuvant delivery itself can act as a potent immune 
adjuvant especially in particulate based systems. 
 
2.3 CHARGED PARTICLES FOR DRUG DELIVERY 
The charge of a particle can affect the way that the particles are recognized and 
taken up by cells.  The surface of a cell is anionic, so any type of charge that a particle or 
material has can affect the way the material interacts with the surface of a cell.  For 
example, using a model particle system (polystyrene spheres) cationically modified 
particles demonstrated a nearly ten-fold increase in cellular interaction as compared to 
non-modified anionic counterparts, most likely due to electrostatic interactions of the 
positively charged particles with the negatively charged cell membrane (Foged et al., 
2005).  The increase in the particle-cell interaction may ultimately lead to an increase in 
non-specific cellular internalization of particles by DCs because they internalize 
exogenous antigens by fluid-phase pinocytosis in addition to receptor-mediated 
endocytosis.  Similarly, when PLGA nanoparticles were functionalized with protamine 
(with an encapsulated model antigen, OVA) it was shown that the cationic 
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functionalization increased not only the uptake of the particles by BMDCs but also 
resulted in a significant increase in BMDC surface activation markers as well as secretion 
of cytokines indicative of a Th1 type immune response (Han et al., 2011).  Interestingly, 
when investigating cationic polymers (polyethylenimine (PEI), polylysine, cationic 
dextran and cationic gelatin) the polymers alone were shown to cause in increase in 
cytokine production associated with Th1 type response by activating the TLR-4 pathway 
(Chen et al., 2010).  Interestingly, when looking at many of the same cationic materials 
(aminodextran, chitosan, PEI, poly(L-lysine) and protamine) coated onto PLGA 
microparticles showed that the particles alone did not induce any significant amount of 
differentiation in DCs and, further, did not alter the way DCs differentiated when in the 
presence of stimulatory molecules (Fischer et al., 2007).   
Cationic microparticles have been extensively researched for their usage in DNA 
vaccine systems and have been shown to be effective delivery systems for surface 
adsorbed-DNA based vaccines capable of inducing significantly enhanced antibody and 
CTL responses to the plasmid (Singh et al., 2000).  Specifically, the antigen encoded in 
the plasmid was presented as a peptide epitope on the MHC class I molecule and, further, 
was shown to be more a more efficient transfection reagent then lipofectamine (a 
commercially available non-viral transfection reagent) (Denis-Mize et al., 2000).  The 
effects seen were thought to have been a result of endosomal disruption and increased 
cytoplasmic or nuclear localization (Denis-Mize et al., 2000).  The adjuvant effects of 
CpG (while delivered with p55 protein antigen on a separate particle) were seen only 
when it was administered in combination (surface loaded) with cationic PLGA particles 
(Singh et al., 2001)).  This increase in activation observed when CpG was surface loaded 
on a particle as compared to soluble is in agreement with other studies investigating 
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different particulate based systems and with different antigens (Cai et al., 2008) (Zwiorek 
et al., 2008).    
Polyethyleneimine (PEI) has been recognized among non-viral cationic 
transfection reagents as one of the most efficient vectors for delivering DNA to the cell 
nucleus while avoiding lysosomal degradation, a key limiting factor in cellular 
transfection (Godbey et al., 1999).  Linear PEI has been shown, however, to be cytotoxic 
when administered at high enough dosages to result in successful cellular transfection 
(Chollet et al., 2002).  Adsorbed PEI onto PLA microparticles is capable of transfecting 
cells in vitro as well as offering protection of surface loaded DNA from DNAse 
degradation (Basarkar et al., 2007).  Further, PEI coated PLGA nanoparticles were shown 
to be able to efficiently deliver surface loaded siRNA to cells in vitro and silence the 
production of proteins in a cell line (Wang et al., 2010).  Interestingly, when PLGA 
nanoparticles were prepared using a single step-PEI coating procedure (i.e. the particles 
were coated with PEI during initial nanoparticle formation as compared to coating post- 
nanoparticle formation) they showed higher transfection capability and showed an 
increase in cell viability as compared to non-adsorbed PEI (Shau et al., 2012).  Simply 
adsorbing cationic molecules to the surface of PLGA microparticles can sometimes, 
however, be unstable, with the cationic material desorbing (Wischke et al., 2006).  It is 
with this in mind that our laboratory focused on actually conjugating a cationic polymer 
to the surface of our particles.  Our lab has found that by conjugating PEI to the surface 
of PLGA microparticles we are able to greatly reduce the cytotoxicity usually associated 
with PEI (Kasturi et al., 2005).   
Anionic particles for the delivery of cationic proteins is, though not as widely 
studied, an emerging field.  A novel nanoparticle system made from a combination of 
PLGA and poly(styrene-co-4-syrene-sulfonate) (PSS) was used to load cationic model 
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antigens (lysozyme and BSA) showed that negatively charged particles were capable of 
loading the protein and showed that its ability to load was directly increased as a function 
of the anionic polymer (PSS).  Further they systematically altered protein loading 
conditions (pH, ionic concentrations) and were able to maximize loading efficiency using 
these two buffer conditions by driving electrostatic interactions (Cai et al., 2008).   
 
2.4 SURFACE LOADING ON PARTICLES 
Biodegradable polymeric particles have received considerable attention as a 
possible means for delivering vaccine antigens.  PLGA has been extensively investigated 
as a possible vaccine delivery agent because it is biocompatible and resorbablity. In fact, 
PLGA has already been commercialized for the delivery of protein and peptide-based 
drugs.  Further, PLGA has been widely used to deliver encapsulated protein antigens 
where by delivering a time-released protein may offer several advantages including 
eliminating the need for booster vaccinations (Jiang et al., 2005).  A major problem 
hindering the progression of microparticle-based vaccine formulations for human use is 
the issue of antigen stability during microencapsulation, storage, and release (as reviewed 
(Weert et al., 2000; Ye et al., 2010)).  In the case of a protein-based vaccine, preserving 
the protein structure is one of the primary concerns and is an impediment in 
microencapsulation processes currently used.  Further, it has been suggested, as in the 
case of PLGA particles, a local pH drop inside the microparticles due to trapped acid 
which is part of the PLGA degradation products can actually further increase protein 
instability and damage the protein structure (as reviewed in (Weert et al., 2000; Ye et al., 
2010)).  Because surface adsorption of proteins can be done under milder conditions this 
technique offers an alternative to the harsh and possibly degradative conditions 
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associated with microencapsulation (O’Hagan et al., 2004; Singh et al., 2004a, 2004b, 
2004c).  Although studies have suggested that protein adsorption is primarily controlled 
by electrostatic interactions, hydrophobic interactions between the protein and particle 
surface can also affect protein loading (Cui et al., 2004; Soppimath et al., 2001).   Protein 
loading will, however, be limited by the actual surface size of the particle.  In spite of 
these limitations, formulations have performed well in animal models eliciting enhanced 
humoral and cellular immune responses to model bacterial and viral antigens (Ataman-
&Ouml;nal et al., 2006; Cui et al., 2004; Jung et al., 2001; Kazzaz et al., 2000).  More 
recently it has been shown that two different antigens can be adsorbed together onto 
particulate carriers.  The structural integrity of the proteins was extremely well 
maintained following adsorption and the particulate formulation was immunogenic for 
both antigens in vivo (Lamalle-Bernard et al., 2006).   
 
2.5 PLASMA MODIFICATION 
Chemical methods can have a variety of potential drawbacks.  In the case of 
particles with encapsulated materials, it may be possible that during a wet chemical 
reaction, hydrophilic encapsulated molecules may begin to release from the 
microparticles lowering the overall encapsulation efficiency. Chemical modification of 
the surface of degradable polymeric particles may also result in the partial degradation 
and scission of the exposed polymer at the surface, leading to accelerated degradation 
when the material is actually injected within the body.  Plasma can be defined as a 
partially ionized gas and consists of a collection of ions, free radicals, and electrons 
produced when a gas is transformed into a high energy, excited state by exposure to an 
energy source under the right physical conditions.  Its applications in biomaterial 
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engineering have widely increased and have been recently reviewed by Desmet et al. 
(Desmet et al., 2009). 
Plasma treatment of a surface can have a variety of consequences.  Typically, the 
surface wettability is increased, functional groups are introduced, roughness is increased, 
and chain scission and/or cross-linking can occur.  The exact functionalities that may be 
introduced can be altered by using different gases as the source of plasma during 
treatment.  O2 plasma treatment has been shown to introduce oxygen-containing 
functional groups, such as carboxylic acid groups, peroxide groups, and hydroxyl groups, 
into the polymer backbone.  On the other hand, free radicals are introduced in the 
backbone of polymers that are treated with Ar or He plasma. When these free radicals are 
subjected to the atmosphere peroxides and hydroperoxides will be formed on their 
surface.  The introduced functionalities can be subsequently used to bind other molecules 
to the surface.  In addition to increasing hydrophilicity, plasma treated PLGA films have 
been shown to adsorb more protein then non-treated films (Lee et al., 2007).  
Furthermore, assuming conditions are optimized, plasma modification appears to have 
little effect on the degradation profile of plasma treated PLGA films (Holy et al., 2001).  
Moreover, when compared to wet chemical modification methods to achieve the same 
surface functionality, plasma modification has been shown to be less detrimental to 3D 
structure (Djordjevic et al., 2008).  These material properties are greatly affected by the 
type of plasma treatment, gases used, and duration of plasma exposure.  Surface 
roughness (as characterized by atomic force microscopy) of O2 plasma treated PLGA 
films, for example, showed significant increases in inter-peak width and valley depth 
dependent on the plasma exposure time.  Furthermore, it was shown that cell attachment 
to these surfaces was also dependent on plasma treatment time, where samples exposed 
for the longest period of time (20 minutes) resulted in reduced cell attachment as 
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compared to cell attachment to surfaces exposed for shorter times (though still showed an 
increase in cell attachment as compared to non-treated PLGA controls) (Wan et al., 
2004).  Ultimately, the focus of the delivery system needs to be in end application.  Each 
particulate based system needs to be specifically tailored to the disease model in question, 
the choice of antigen as well as adjuvant must be specific to the disease state and will 
ultimately dictate the type of particle that will be most beneficial for delivery. 
 
2.6 CANCER VACCINES 
Cancer is currently the second most common cause of death in the United States 
with 580,350 Americans expected to die of cancer in 2013 (American Cancer Society, 
2013).  Further, The National Institute of Health estimates that the over-all costs of 
cancer in 2008 were up to $201.5 billion (American Cancer Society, 2013).  While 
survival rates have increased, obvious actions need to be taken to prevent and treat 
cancer.  Vaccination strategies in cancer immunotherapy research have been focused 
mostly in developing prophylactic therapies to prevent cancer, therapeutic vaccines to 
destroy already developed tumors, as well as post-surgery treatment (for treatment after 
solid tumors have been excised to prevent tumors from re-growing) and focus on 
developing a T cell driven immune response.  T cell based immunity is more attractive 
than humoral immunity because anti-bodies work by targeting proteins that need to be 
expressed on the surface of cells whereas T cells can target peptides derived from 
intracellular proteins.  All of these therapies have had their issues but hold promise for 
further development. 
Therapeutic cancer vaccines need to act in the same way that a vaccine would for 
a microbial pathogen, inducing an immune response against the body’s own (and thus 
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non-immunogenic) cells.  As reviewed by Rosenberg et al the field of cancer 
immunotherapy when it comes to vaccines is a booming field, with hundreds of vaccine 
clinical trials in patients despite the absence of convincing supporting animal data that the 
vaccines alone could affect invasive, vascularized tumors (Rosenberg et al., 2004).  Part 
of the problems in using vaccines in a therapeutic manner after tumor removal is that the 
microenvironment before/during initial tumor growth progression and for a recurrent 
tumor is very different (Predina et al., 2013).  These changes might be a result of a 
number of different events including a shift in the dominating population of immune cells 
or changes in cytokine production locally as a result of the bodies’ own wound healing 
response (Predina et al., 2013).  These results indicate that a treatment based vaccine 
system for recurrent tumors may need to modulate the local tumor microenvironment 
differently.  Currently, one of the most therapeutically relevant treatments is one that is 
DC based, Sipuleucel-T.   
 
2.7 DENDRITIC CELLS AS VACCINES 
Since Ralph Steinman’s discovery of DCs in 1973, their importance in immunity 
has been undeniable and they have emerged as a potential target cell population given 
their ability to induce both the innate and adaptive immune response despite having a 
misleadingly low number (1%) of the overall cell population (as reviewed recently by 
Palucka et al. (Palucka and Banchereau, 2012)).  While pathogens found in the human 
body have found ways to hijack DCs to manipulate the immune system only recently 
have immunologists begun to attempt to do the same to design vaccines (Pulendran et al., 
2001).  By studying how microbes are capable of manipulating DC function as well as 
the receptors and signaling pathways through which they act and then using this gained 
 23 
knowledge to, in turn, manipulate DCs in a controlled manner it may be possible to move 
forward in rational vaccine design and eventually manipulate the appropriate DC 
subpopulations in vivo (Pulendran et al., 2001).  DCs pulsed, ex vivo, with antigens have 
been shown to offer protective immunity that is antigen specific and, further, the 
immunity offered was dependent on CD8
+
 T cells (Celluzzi et al., 1996).   
Sipuleucel-T is a cellular based vaccine consisting of autologous peripheral-blood 
mononuclear cells activated with a novel recombinant fusion protein.  The fusion protein, 
called PA2024 consists not only of the antigen (one for prostate cancer) but also prostatic 
acid phosphatase and both are fused to granulocyte-macrophage colony-stimulating 
factor (GM-CSF).  GM-CSF itself has been widely investigated for usage in cancer 
vaccines given that it has demonstrated an enhanced protection from tumor re-challenge 
(where the GM-CSF was produced by transfected tumor cells).  Interestingly, as reviewed 
in Klebanoff et al.’s review of cancer vaccines, most clinical trials involving GM-CSF 
actually had detrimental effects in the vaccine systems it was tested with instead of 
having the adjuvant effect expected (Klebanoff et al., 2011).  Sipuleucel-T was shown to 
increase a patients’ life by 4.1 months as compared to the placebo group (Kantoff et al., 
2010).   
Research has also been done on developing a therapeutic dendritic cell based 
vaccine for HIV treatment (García and Routy, 2011).  While vaccinations of this type 
have been shown to enhance HIV-specific immune responses, there was no clear 
indication that there was any improved clinical outcome in patients, theorized to be a 
result of an immune system that was already far too damaged by the disease for the 
vaccine to make any measurable difference (Allard et al., 2012).  That being said, a 
measurable increase in immune cells specific to the proteins the DCs had been 
transfected to express indicates that this may be a therapy worth continuing investigation.  
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In another DC based approach, DCs were treated ex vivo with autologous heat-inactivated 
HIV-1 before being delivered to the patient (García et al., 2013).  Using this therapy they 
showed significant decreases in plasma viral load accompanied by increases in T cells 
specific for HIV-1 . 
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Haemophilus influenza type B 
Pneumococcus 
Meningococcus group C 




This table was modified from the table (Plotkin, 2003) found in The Vaccine 
Book and is meant for demonstrative purposes and is not meant to be a comprehensive 
list of vaccines.   
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Table 2.2:  Potential TLR Targets for Adjuvants 




Surface TLRs and 
agonists 
Triacyl lipopeptides, Pam3Cys TH0, TH2 TLR 2 
Diacyl lipopeptides, Lipoteichoic 
acids, Zymosan 
TH0, TH2 TLR 2 
Peptidoglycan, muropeptides, MDP  TLR 2 
LPS, MPL, LPS analogues, Taxol TH1 TLR 4 
Flagellin TH1 TLR 5 
Uropathogenic bacteria, Toxoplasma 
profiling 
TH1 TLR 11 
Endosome TLRs and 
agonists 
dsRNA, Poly(I:C) TH1 TLR 3 
Unmethylated CpG DNA, synthetic 
oligonucleotides 
TH1 TLR 9 
Imidazoquinoline  TLR 7 
TLR 8 
This chart was modified from a figure from (Guy, 2007; Leleux and Roy, 2013a). 
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Table 2.3:  Challenges in vaccine biology requiring improved control of antigen 
presentation 
Enhance antibody and T cell-mediated immune memory 
Improve the quality of the T cell response 
Design therapeutic as well as preventative vaccines 
Identify vaccines that dampen immunity 




Table 2.4:  Peptide vaccine immunization of patients with metastatic cancer 
Peptide Total 
Patients 
NR PR CR 
MART-127-35 23 22 1 0 
MART-227-35+IL-12 23 12 0 0 
gp100209-217 9 8 0 1 





16 14 2 0 
Dendritic cells + g209-2M + MART-27L 15 13 2 0 
*This list is meant to be demonstrative not exhaustive.  Adapted from (Rosenberg 
et al., 2004).  Abbreviations are as follows:  CR are patients demonstrating complete 
responsiveness, PR are patients demonstrating partial responsiveness, and NR are patients 




Figure 2.1 Dendritic Cell maturation:  Modified from (Banchereau et al., 2000) to 
represent main differences in function of immature and mature dendritic 





Aichele, P., Brduscha-Riem, K., Zinkernagel, R.M., Hengartner, H., and Pircher, H. 
(1995). T cell priming versus T cell tolerance induced by synthetic peptides. J 
Exp Med 182, 261–266. 
Akira, S., and Takeda, K. (2004). Toll-like receptor signalling. Nat Rev Immunol 4, 499–
511. 
Allard, S.D., De Keersmaecker, B., de Goede, A.L., Verschuren, E.J., Koetsveld, J., 
Reedijk, M.L., Wylock, C., De Bel, A.V., Vandeloo, J., Pistoor, F., et al. (2012). 
A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and 
Nef expressing dendritic cells followed by treatment interruption. Clinical 
Immunology 142, 252–268. 
American Cancer Society (2013). Cancer Facts & Figures 2013. 
Arnon, R., and Horwitz, R.J. (1992). Synthetic peptides as vaccines. Current Opinion in 
Immunology 4, 449–453. 
Ataman-&Ouml;nal, Y., Ataman-&Ouml, nal, Y., Munier, S., verine, Gan&eacute, e, A., 
Terrat, C., line, Durand, P.-Y., et al. (2006). Surfactant-free anionic PLA 
nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and 
humoral immune responses in various animal models. Journal of Controlled 
Release 112, 175–185. 
Banchereau, J., and Steinman, R.M. (1998). Dendritic cells and the control of immunity. 
Nature 392, 245–252. 
Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y.-J., Pulendran, B., 
and Palucka, K. (2000). Immunobiology of Dendritic Cells. Annual Review of 
Immunology 18, 767–811. 
Basarkar, A., Devineni, D., Palaniappan, R., and Singh, J. (2007). Preparation, 
characterization, cytotoxicity and transfection efficiency of poly(dl-lactide-co-
glycolide) and poly(dl-lactic acid) cationic nanoparticles for controlled delivery of 
plasmid DNA. International Journal of Pharmaceutics 343, 247–254. 
Bharali, D.J., Pradhan, V., Elkin, G., Qi, W., Hutson, A., Mousa, S.A., and Thanavala, Y. 
(2008). Novel nanoparticles for the delivery of recombinant hepatitis B vaccine. 
Nanomedicine: Nanotechnology, Biology and Medicine 4, 311–317. 
Van der Bruggen, P., Stroobant, V., Vigneron, N., and Van den Eynde, B. (2013). Peptide 
database:  T cell-defined tumor antigens. 
Cai, C., Bakowsky, U., Rytting, E., Schaper, A.K., and Kissel, T. (2008). Charged 
nanoparticles as protein delivery systems: A feasibility study using lysozyme as 
model protein. European Journal of Pharmaceutics and Biopharmaceutics 69, 31–
42. 
 31 
Cella, M., Engering, A., Pinet, V., Pieters, J., and Lanzavecchia, A. (1997). Inflammatory 
stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 
388, 782–787. 
Celluzzi, C.M., Mayordomo, J.I., Storkus, W.J., Lotze, M.T., and Falo, L.D. (1996). 
Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective 
tumor immunity. J Exp Med 183, 283–287. 
Chen, H., Li, P., Yin, Y., Cai, X., Huang, Z., Chen, J., Dong, L., and Zhang, J. (2010). 
The promotion of type 1 T helper cell responses to cationic polymers in vivo via 
toll-like receptor-4 mediated IL-12 secretion. Biomaterials 31, 8172–8180. 
Chollet, P., Favrot, M.C., Hurbin, A., and Coll, J.-L. (2002). Side-effects of a systemic 
injection of linear polyethylenimine-DNA complexes. J Gene Med 4, 84–91. 
Cole, D.K., Edwards, E.S.J., Wynn, K.K., Clement, M., Miles, J.J., Ladell, K., Ekeruche, 
J., Gostick, E., Adams, K.J., Skowera, A., et al. (2010). Modification of MHC 
Anchor Residues Generates Heteroclitic Peptides That Alter TCR Binding and T 
Cell Recognition. J Immunol 185, 2600–2610. 
Cui, Z., Patel, J., Tuzova, M., Ray, P., Phillips, R., Woodward, J.G., Nath, A., and 
Mumper, R.J. (2004). Strong T cell type-1 immune responses to HIV-1 Tat (1–72) 
protein-coated nanoparticles. Vaccine 22, 2631–2640. 
Davis, H.L., Weeranta, R., Waldschmidt, T.J., Tygrett, L., Schorr, J., and Krieg, A.M. 
(1998). CpG DNA Is a Potent Enhancer of Specific Immunity in Mice Immunized 
with Recombinant Hepatitis B Surface Antigen. J Immunol 160, 870–876. 
Denis-Mize, K.S., Dupuis, M., MacKichan, M.L., Singh, M., Doe, B., O’Hagan, D., 
Ulmer, J.B., Donnelly, J.J., McDonald, D.M., and Ott, G. (2000). Plasmid DNA 
adsorbed onto cationic microparticles mediates target gene expression and antigen 
presentation by dendritic cells. Gene Therapy 7, 2105–2112. 
Desmet, T., Morent, R., De Geyter, N., Leys, C., Schacht, E., and Dubruel, P. (2009). 
Nonthermal plasma technology as a versatile strategy for polymeric biomaterials 
surface modification: a review. Biomacromolecules 10, 2351–2378. 
Djordjevic, I., Britcher, L.G., and Kumar, S. (2008). Morphological and surface 
compositional changes in poly(lactide-co-glycolide) tissue engineering scaffolds 
upon radio frequency glow discharge plasma treatment. Applied Surface Science 
254, 1929–1935. 
Fischer, S., Uetz-von Allmen, E., Waeckerle-Men, Y., Groettrup, M., Merkle, H.P., and 
Gander, B. (2007). The preservation of phenotype and functionality of dendritic 
cells upon phagocytosis of polyelectrolyte-coated PLGA microparticles. 
Biomaterials 28, 994–1004. 
 32 
Foged, C., Brodin, B., Frokjaer, S., and Sundblad, A. (2005). Particle size and surface 
charge affect particle uptake by human dendritic cells in an in vitro model. Int J 
Pharm 298, 315–322. 
García, F., and Routy, J.-P. (2011). Challenges in dendritic cells-based therapeutic 
vaccination in HIV-1 infection: Workshop in dendritic cell-based vaccine clinical 
trials in HIV-1. Vaccine 29, 6454–6463. 
García, F., Climent, N., Guardo, A.C., Gil, C., León, A., Autran, B., Lifson, J.D., 
Martínez-Picado, J., Dalmau, J., Clotet, B., et al. (2013). A Dendritic Cell–Based 
Vaccine Elicits T Cell Responses Associated with Control of HIV-1 Replication. 
Sci Transl Med 5, 166ra2–166ra2. 
Godbey, W.T., Wu, K.K., and Mikos, A.G. (1999). Poly(ethylenimine) and its role in 
gene delivery. Journal of Controlled Release 60, 149–160. 
Guy, B. (2007). The perfect mix: recent progress in adjuvant research. Nat Rev Micro 5, 
505–517. 
Han, R., Zhu, J., Yang, X., and Xu, H. (2011). Surface modification of poly(D,L-lactic-
co-glycolic acid) nanoparticles with protamine enhanced cross-presentation of 
encapsulated ovalbumin by bone marrow-derived dendritic cells. Journal of 
Biomedical Materials Research Part A 96A, 142–149. 
Hartmann, G., Weiner, G.J., and Krieg, A.M. (1999). CpG DNA: A potent signal for 
growth, activation, and maturation of human dendritic cells. PNAS 96, 9305–
9310. 
Holy, C.E., Cheng, C., Davies, J.E., and Shoichet, M.S. (2001). Optimizing the 
sterilization of PLGA scaffolds for use in tissue engineering. Biomaterials 22, 25–
31. 
Hubbell, J.A., Thomas, S.N., and Swartz, M.A. (2009). Materials engineering for 
immunomodulation. Nature 462, 449–460. 
Jiang, W., Gupta, R.K., Deshpande, M.C., and Schwendeman, S.P. (2005). 
Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery 
of vaccine antigens. Advanced Drug Delivery Reviews 57, 391–410. 
Jung, T., Kamm, W., Breitenbach, A., Hungerer, K.-D., Hundt, E., and Kissel, T. (2001). 
Tetanus Toxoid Loaded Nanoparticles from Sulfobutylated Poly(Vinyl Alcohol)-
Graft-Poly(Lactide-co-Glycolide): Evaluation of Antibody Response After Oral 
and Nasal Application in Mice. Pharm Res 18, 352–360. 
Kantoff, P.W., Higano, C.S., Shore, N.D., Berger, E.R., Small, E.J., Penson, D.F., 
Redfern, C.H., Ferrari, A.C., Dreicer, R., Sims, R.B., et al. (2010). Sipuleucel-T 
Immunotherapy for Castration-Resistant Prostate Cancer. New England Journal of 
Medicine 363, 411–422. 
 33 
Kasturi, S.P., Sachaphibulkij, K., and Roy, K. (2005). Covalent conjugation of 
polyethyleneimine on biodegradable microparticles for delivery of plasmid DNA 
vaccines. Biomaterials 26, 6375–6385. 
Kazzaz, J., Neidleman, J., Singh, M., Ott, G., and O’Hagan, D.T. (2000). Novel anionic 
microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes 
against recombinant p55 gag from HIV-1. J Control Release 67, 347–356. 
Klebanoff, C.A., Acquavella, N., Yu, Z., and Restifo, N.P. (2011). Therapeutic cancer 
vaccines: are we there yet? Immunological Reviews 239, 27–44. 
Klinman, D.M., Barnhart, K.M., and Conover, J. (1999). CpG motifs as immune 
adjuvants. Vaccine 17, 19–25. 
Kool, M., Fierens, K., and Lambrecht, B.N. (2011). Alum adjuvant: some of the tricks of 
the oldest adjuvant. Journal of Medical Microbiology 61, 927–934. 
Krieg, A.M. (2002). Cpg Motifs in Bacterial Dna and Their Immune Effects*. Annual 
Review of Immunology 20, 709–760. 
Lamalle-Bernard, D., Munier, S., Compagnon, C., Charles, M.-H., Kalyanaraman, V.S., 
Delair, T., Verrier, B., and Ataman-Önal, Y. (2006). Coadsorption of HIV-1 p24 
and gp120 proteins to surfactant-free anionic PLA nanoparticles preserves 
antigenicity and immunogenicity. Journal of Controlled Release 115, 57–67. 
Lee, S.G., An, E. young, Lee, J.B., Park, J.C., Shin, J.W., and Kim, J.K. (2007). 
Enhanced cell affinity of poly(d,l-lactic-co-glycolic acid) (50/50) by plasma 
treatment with β-(1 → 3) (1 → 6)-glucan. Surface and Coatings Technology 201, 
5128–5131. 
Leleux, J., and Roy, K. (2013). Micro and Nanoparticle-Based Delivery Systems for 
Vaccine Immunotherapy: An Immunological and Materials Perspective. 
Advanced Healthcare Materials 2, 72–94. 
Lipford, G.B., Bauer, M., Blank, C., Reiter, R., Wagner, H., and Heeg, K. (1997). CpG-
containing synthetic oligonucleotides promote B and cytotoxic T cell   responses 
to protein antigen: a new class of vaccine adjuvants. Eur. J. Immunol. 27, 2340–
2344. 
Mahnke, K., Schmitt, E., Bonifaz, L., Enk, A.H., and Jonuleit, H. (2002). Immature, but 
not inactive: the tolerogenic function of immature dendritic cells. Immunol Cell 
Biol 80, 477–483. 
Mosca, F., Tritto, E., Muzzi, A., Monaci, E., Bagnoli, F., Iavarone, C., O’Hagan, D., 
Rappuoli, R., and Gregorio, E.D. (2008). Molecular and cellular signatures of 
human vaccine adjuvants. PNAS 105, 10501–10506. 
Nicholson, K.G., Colegate, A.E., Podda, A., Stephenson, I., Wood, J., Ypma, E., and 
Zambon, M.C. (2001). Safety and antigenicity of non-adjuvanted and MF59-
 34 
adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of 
two potential vaccines against H5N1 influenza. The Lancet 357, 1937–1943. 
O’Hagan, D.T., Singh, M., and Ulmer, J.B. (2004). Microparticles for the delivery of 
DNA vaccines. Immunol. Rev. 199, 191–200. 
Palucka, K., and Banchereau, J. (2012). Cancer immunotherapy via dendritic cells. Nat 
Rev Cancer 12, 265–277. 
Park, J., Wu, C.T., and Bryers, J.D. (2013). Chemokine programming dendritic cell 
antigen response: part I - select chemokine programming of antigen uptake even 
after maturation. Immunology 139, 72–87. 
Pierre, P., Turley, S., Gatti, E., Hull, M., Meltzer, J., Mizra, A., Inaba, K., Steinman, R., 
and Mellman, I. (1997). Developmental regulation of MHC class II transport in 
mouse dendritic cells. Nature 388, 787–792. 
Plotkin, S. (2003). Disease States and Vaccines:  Selected Cases. In The Vaccine Book, 
(San Diego, California: Academic Press), pp. 179–188. 
Predina, J., Eruslanov, E., Judy, B., Kapoor, V., Cheng, G., Wang, L.-C., Sun, J., Moon, 
E.K., Fridlender, Z.G., Albelda, S., et al. (2013). Changes in the local tumor 
microenvironment in recurrent cancers may explain the failure of vaccines after 
surgery. PNAS 110, E415–E424. 
Pulendran, B., Palucka, K., and Banchereau, J. (2001). Sensing Pathogens and Tuning 
Immune Responses. Science 293, 253–256. 
Purcell, A.W., McCluskey, J., and Rossjohn, J. (2007). More than one reason to rethink 
the use of peptides in vaccine design. Nat Rev Drug Discov 6, 404–414. 
Rosenberg, S.A., Yang, J.C., and Restifo, N.P. (2004). Cancer immunotherapy: moving 
beyond current vaccines. Nat Med 10, 909–915. 
Rosenberg, S.A., Yang, J.C., Kammula, U.S., Hughes, M.S., Restifo, N.P., Schwarz, 
S.L., Morton, K.E., Laurencot, C.M., and Sherry, R.M. (2010). Different 
Adjuvanticity of Incomplete Freundʼs Adjuvant Derived From Beef or Vegetable 
Components in Melanoma Patients Immunized With a Peptide Vaccine. Journal 
of Immunotherapy 33, 626–629. 
Rutella, S., Danese, S., and Leone, G. (2006). Tolerogenic dendritic cells: cytokine 
modulation comes of age. Blood 108, 1435–1440. 
Sato, M., Iwakabe, K., Kimura, S., and Nishimura, T. (1999). Functional skewing of bone 
marrow-derived dendritic cells by Th1- or Th2-inducing cytokines. Immunol. 
Lett. 67, 63–68. 
Sette, A., and Fikes, J. (2003). Epitope-based vaccines: an update on epitope 
identification, vaccine design and delivery. Current Opinion in Immunology 15, 
461–470. 
 35 
Shau, M.D., Shih, M.F., Lin, C.C., Chuang, I.C., Hung, W.C., Hennink, W.E., and 
Cherng, J.Y. (2012). A one-step process in preparation of cationic nanoparticles 
with poly(lactide-co-glycolide)-containing polyethylenimine gives efficient gene 
delivery. European Journal of Pharmaceutical Sciences 46, 522–529. 
Singh, A., Nie, H., Ghosn, B., Qin, H., Kwak, L.W., and Roy, K. (2008). Efficient 
Modulation of T-cell Response by Dual-mode, Single-carrier Delivery of 
Cytokine-targeted siRNA and DNA Vaccine to Antigen-presenting Cells. 
Molecular Therapy 16, 2011–2021. 
Singh, M., Briones, M., Ott, G., and O’Hagan, D. (2000). Cationic microparticles: A 
potent delivery system for DNA vaccines. PNAS 97, 811–816. 
Singh, M., Ott, G., Kazzaz, J., Ugozzoli, M., Briones, M., Donnelly, J., and O’Hagan, 
D.T. (2001). Cationic Microparticles Are an Effective Delivery System for 
Immune Stimulatory CpG DNA. Pharm Res 18, 1476–1479. 
Singh, M., Kazzaz, J., Chesko, J., Soenawan, E., Ugozzoli, M., Giuliani, M., Pizza, M., 
Rappouli, R., and O’Hagan, D.T. (2004a). Anionic microparticles are a potent 
delivery system for recombinant antigens from Neisseria meningitidis serotype B. 
Journal of Pharmaceutical Sciences 93, 273–282. 
Singh, M., Chesko, J., Kazzaz, J., Ugozzoli, M., Kan, E., Srivastava, I., and O’Hagan, 
D.T. (2004b). Adsorption of a novel recombinant glycoprotein from HIV (Env 
gp120dV2 SF162) to anionic PLG microparticles retains the structural integrity of 
the protein, whereas encapsulation in PLG microparticles does not. Pharm. Res. 
21, 2148–2152. 
Singh, M., Kazzaz, J., Ugozzoli, M., Chesko, J., and O’Hagan, D.T. (2004c). Charged 
polylactide co-glycolide microparticles as antigen delivery systems. Expert Opin 
Biol Ther 4, 483–491. 
Soppimath, K.S., Aminabhavi, T.M., Kulkarni, A.R., and Rudzinski, W.E. (2001). 
Biodegradable polymeric nanoparticles as drug delivery devices. Journal of 
Controlled Release 70, 1–20. 
Steinman, R.M., and Pope, M. (2002). Exploiting dendritic cells to improve vaccine 
efficacy. Journal of Clinical Investigation 109, 1519–1526. 
Trollfors, B., Bergfors, E., and Inerot, A. (2005). Vaccine related itching nodules and 
hypersensitivity to aluminium. Vaccine 23, 975–976. 
Wan, Y., Qu, X., Lu, J., Zhu, C., Wan, L., Yang, J., Bei, J., and Wang, S. (2004). 
Characterization of surface property of poly(lactide-co-glycolide) after oxygen 
plasma treatment. Biomaterials 25, 4777–4783. 
Wang, J., Feng, S.-S., Wang, S., and Chen, Z. (2010). Evaluation of cationic 
nanoparticles of biodegradable copolymers as siRNA delivery system for hepatitis 
B treatment. International Journal of Pharmaceutics 400, 194–200. 
 36 
Weert, M. van de, Hennink, W.E., and Jiskoot, W. (2000). Protein Instability in 
Poly(Lactic-co-Glycolic Acid) Microparticles. Pharm Res 17, 1159–1167. 
Wischke, C., Borchert, H.-H., Zimmermann, J., Siebenbrodt, I., and Lorenzen, D.R. 
(2006). Stable cationic microparticles for enhanced model antigen delivery to 
dendritic cells. J Control Release 114, 359–368. 
Ye, M., Kim, S., and Park, K. (2010). Issues in long-term protein delivery using 
biodegradable microparticles. Journal of Controlled Release 146, 241–260. 
Ben-Yedidia, T., and Arnon, R. (1997). Design of peptide and polypeptide vaccines. 
Current Opinion in Biotechnology 8, 442–448. 
Zwiorek, K., Bourquin, C., Battiany, J., Winter, G., Endres, S., Hartmann, G., and 
Coester, C. (2008). Delivery by Cationic Gelatin Nanoparticles Strongly Increases 








Plasma Surface Modification of PLGA Microparticles for Efficient 
Anionic Protein Loading 
3.1 INTRODUCTION: 
This chapter describes work done in collaboration with Dr. Laxminarayana Raja’s 
lab in the Department of Aerospace engineering at the University of Texas at Austin.  
Briefly, we examined the effects of using plasma technology to alter the surface of PLGA 
microparticles.  Dr. Raja’s dielectric barrier glow discharge system was used to create an 
atmospheric glow discharge plasma (APG).  We investigated altering a variety of 
conditions associated with the formation of this kind of plasma to find conditions that 
imparted significant changes in zeta potential.  We also studied the effects of using a low-
pressure plasma system on zeta potential, protein loading, and surface modification over 
time.  These studies offer important and interesting proof-of-concept in using plasma as a 
dry-chemical process to add functional groups to the surface of microparticles.  We 
showed that the atmospheric system that Dr. Raja developed was able to impart a 
significant amount of anionic charge on the surface of our PLGA microparticles.  This 
charge varied depending on the frequency of the applied voltage.  While the dielectric 
material is very important in plasma formation, no significant change in particle zeta 
potential was observed as a function of this variable.  Ovalbumin was loaded onto the 
microparticles at a loading efficiency of 36%.  Low pressure plasma was also 
investigated as an alternative to the APG system for usage.  We looked at using different 
gasses, specifically He and O2 plasma and while little difference in charge was observed, 
SEM images revealed a slightly rougher surface on the O2 plasma exposed particles.  
Lysozyme was electrostatically attached to the particles at close to 100% loading 
efficiency.  Unfortunately, it seems that the surface of our particles “age” and zeta 
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potential is lost over time.  Thus, more work needs to be done to investigate possible 
storage solutions for usage of these materials. 
 
3.2 BACKGROUND AND MOTIVATION 
The surface properties of materials play a very important role in the overall 
function and biocompatibility of a material.  One major concern when dealing with a 
material that comes into contact with extracellular fluids is the way that material will 
interact with proteins found in plasma.  Because of this, ultimately you are dealing with a 
two very separate issues in selecting a single material.  The material needs to have 
specific bulk properties while also interacting favorably with extracellular fluids.  This is 
a difficult set of properties for a single material to meet.  For this reason, many different 
methods of altering surface properties have been investigated, including:  
coating/adsorption, plasma modification, or chemically grafting another material onto the 
surface (Ikada, 1994).   
Most methods for introducing new functional groups onto the surface of materials 
are wet chemical based methods.  While effective, they can also have many undesirable 
effects on a material, especially if that material is biodegradable.  These modification 
techniques can result in a loss of mechanical properties and ultimately lead to a faster 
degradation rate (Desmet et al., 2009; Morent et al., 2011).  In this way, a dry plasma 
based strategy may be beneficial.   
Plasma can be thought of as an ionized gas composed of free electrons, ions, and 
radicals (along with neutral particles).  Plasma is formed when gases are excited by 
applying energy to the gas. It reorganizes the electronic structure of the species and 
produces excited ions.  Plasma reactions themselves are typically broken down into three 
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categories:  plasma polymerization, plasma treatment, and plasma etching (or ablation) 
(reviewed in (Desmet et al., 2009)).  Plasma polymerization involves actually depositing 
monomers onto the surface of a substrate, and etching occurs when the ions from the 
plasma strike the substrate hard enough to actually have an ablative reaction (Desmet et 
al., 2009).  Plasmas can be used to insert chemical groups or radicals onto otherwise non-
reactive surfaces (as reviewed in (Siow et al., 2006)).  Different gasses will introduce 
different functionalities onto the surface of the materials.  He and Ar plasmas typically 
introduce free radicals to the surface of the substrate, which then react with air and 
ultimately lead to the formation of peroxides and hydroperoxides.  O2 based plasmas tend 
to introduce a mixture of carboxylic acid and hydroxide groups (Desmet et al., 2009).  
Plasma modification has been extensively researched in polymeric films (Desmet et al., 
2009; Mattioli et al., 2012; Morent et al., 2011; Wan et al., 2004) but no publications of 
its usage in particles have been reported. 
While most research has focused on using cationic particles for delivering anionic 
protein antigens and other immunomodulatory molecules, there is need for anionic 
particles to deliver cationic molecules, especially protein antigens.  The first group 
credited with adsorbing antigens onto the surface of a particle based delivery system was 
Almeida, Alpar, and Brown (Almeida et al., 1993).  PLGA microparticles prepared with 
anionic surfactants like sodium dodecyl sulfate (SDS) have been shown to be able to 
adsorb p55 gag protein (from HIV-1) and were able to induce CTL responses in mice as 
well as antibody responses (Kazzaz et al., 2000).  Further, work has been done 
investigating the usage of anionic nanoparticles to deliver a protein that had been made 
more positively-charged (the process is referred to as cationization).  Interestingly, the 
cationized protein elicited antibody responses similar to that seen with the non-charged 
protein delivered with alum but the greatest amount of response was seen when the 
 40 
cationized protein was delivered adsorbed onto their anionic particles (Cui and Mumper, 
2002).  Surfactant free PLA nanoparticles surface loaded with the HIV-1 p24 capsid 
protein were able to induce a CTL response in mice without the need for an additional 
adjuvant (as compared to the protein delivered in combination with alum) (Ataman-Önal 
et al., 2006).   
Here we propose the usage of PLGA microparticles charge-functionalized using 
plasma surface modification.  We investigated two plasma sources:  an atmospheric 
plasma glow discharge system and a low pressure plasma system.  With the help of 
Laxminarayana Raja’s lab we began our investigations using a dielectric barrier 
discharge system to create atmospheric glow discharge plasma (Shin and Raja, 2003, 
2007).  This type of system has many advantages from an industrial standpoint, the most 
compelling of which is its cost.  This system eliminates the need for expensive vacuum 
equipment and can actually be scaled up (depending on the size of the electrodes).  The 
main issue in scale up is that there is a greater chance that instabilities in the plasma will 
arise, and the plasma may actually create a thermal arc discharge.  Again, if this transition 
occurs the plasma will no longer be homogenous and the plasma can lose its non-thermal 
nature.  This is why the system used creates plasma in a pulsed regimen.  Another factor 
that works to stabilize the plasma in this system is the dielectric material used to cover 
the electrodes (Tendero et al., 2006).  While APG plasmas have a lot of advantages, low 
pressure systems typically used in semi-conductor work also have their own advantages.  
Using low pressure removes any contaminating molecules/gases creating a free path for 
the gas you are using to create the plasma and interact with your material, making your 
reactions easier to control.  For this reason we looked into using a low pressure system. 
Here we investigated the usage of two different gasses, He and O2.  We investigated a 
number of factors within the plasma production as well as time of exposure to alter the 
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zeta potential of our PLGA microparticles.  We then used our particle formulations to 
load model protein antigens on the surface. 
 
3.3 MATERIALS AND METHODS: 
3.3.1 Reagents  
PLGA Resomer® RG502H, ovalbumin, lysozyme, monosodium phosphate, and 
disodium phosphate were purchased from Sigma-Aldrich.  Poly(vinyl alcohol) PVA MW 
~ 31,000 was purchased from Fluka.  Micro BCA kit for protein analysis was purchased 
from (Thermo Scientific, Rockford, IL).   
 
3.3.2 Plasma surface modification using a novel He gas atmospheric plasma glow 
(APG) discharge system 
PLGA microparticles were prepared as we have previously reported (Kasturi et 
al., 2005; Pai Kasturi et al., 2006; Singh et al., 2008).  Briefly, acid end-capped PLGA 
RG502H (MW ~ 11,000 Da, Sigma-Aldrich) microparticles were prepared using a water-
in-oil-in-water (w/o/w) double emulsion, solvent evaporation technique.  Briefly, 0.2 g of 
PLGA was dissolved in 7 mL of dichloromethane (DCM) (Thermo Fischer Scientific 
Inc., Waltham, MA).  300 μL of deionized water was added to the polymer solution and 
immediately homogenized for 2 minutes.  The emulsion waspoured into a 1% PVA 
solution and homogenized for 2 minutes and then the DCM was evaporated from the 
solution.  The microparticles were collected and washed with deionized water, 
lyophilized and stored at -20°C.  The microparticles were then coated onto glass slides at 
a concentration of 2.5 mg/mL (concentration based on slide coating optimization studies, 
data not shown) in deionized water.  Slides were allowed to dry at room temperature until 
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all water had evaporated (approximately 3 hours) prior to plasma exposure.  PLGA 
microparticles were plasma modified using a novel atmospheric plasma glow (APG) 
discharge system (Shin and Raja, 2003, 2007).  The dielectric barrier discharge system 
consists of two plane-parallel metal electrodes where the electrodes are covered by a 
dielectric material (Figure 3.1).  The two electrodes are separated by a gap that was 
about 3 cm, and He gas is allowed to flow through that gap at a rate of 4.5 standard liters 
per minute (SLPM), and the sample is immobilized over one of the electrodes.  The 
discharge was then initiated by a sinusoidally applied power source.  An outline of the 
experimental objectives can be seen in Figure 3.2.  Because the dielectric layer plays an 
important role in the plasma process by acting to ensure homogenous plasma formation, 
and thus a more homogenous surface treatment, we investigated the usage of different 
dielectric materials in generating anionic surface charge.  Zeta potential was then 
quantified using ZetaPlus (BrookHaven Instruments Corporation, Holtsville, NY).  All 
microparticle samples were suspended in 1 mM KCl.   
 
3.3.3 Low pressure plasma surface treatment of PLGA microparticles 
We also investigated a low pressure plasma system for surface modification.  Just 
as in the case of our APG surface modification, we prepared PLGA microparticles as 
described in section 3.3.1.  We coated the microparticles at a concentration of 5 mg/mL 
on each glass slide.  The PLGA microparticle coated slides were then plasma modified at 
a pressure of 180 mTorr using either oxygen or helium plasma at a rate of 18 SCCM and 
50 Watts using the Plasma Therm 790 Series reactive ion etcher.  The slides were then 
stored in a vacuum chamber and microparticles were removed by resuspension in water 
and either immediately used or lyophilized and stored at -20°C.   
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3.3.4 Protein loading on plasma treated PLGA microparticles 
Ovalbumin or lysozyme (Sigma, Saint Louis, MO) was loaded onto the surface of 
plasma-modified microparticles at 1.2% (w/w) in 10 mM citrate buffer or 10 mM 
phosphate buffer.  Briefly, plasma modified microparticles were added to a dilute 
solution of ovalbumin and allowed to incubate at 4°C overnight on an end over end 
shaker.  Adjusting the pH of our loading buffer enabled us to adsorb greater 
concentrations of protein to our plasma-treated microparticles.  Protein concentration was 
indirectly calculated by measuring the concentration of remaining protein that did not 
adsorb to the particles using a Micro BCA Protein Assay Kit. In other words, the protein 
concentration measured in the supernatant remaining after protein adsorption to the 
particles was subtracted from the initial protein concentration added.   
 
3.3.5 SEM of plasma modified microparticles 
Scanning electron microscopy images were taken of the microparticles after low 
pressure plasma treatment to assess any possible effects (qualitatively) that plasma 
modification may have had on the surface characteristics of the microparticles.  The 
microparticles were coated onto aluminum stubs obtained from the electron microscopy 
facility.  Microparticles were suspended in 0.2 µm filtered purified water and deposited 
on the stubs and allowed to dry overnight.  The microparticle coated stubs were then 
coated with 15 nm of gold:palladium using the sputter coater at the core facility.  The 




3.3.6 Storage conditions 
Long term storage options were investigated for our particles.  First, we assessed 
if lyopholization would change the zeta potential.  After exposure to plasma (low 
pressure plasma for 30 seconds using the Plasma Therm as previously described) PLGA 
microparticles were resuspended in 0.2 µm water and then lyophilized overnight to 
remove water.  Zeta potential analysis was then performed using a Delsa Nano Zeta 
Potential and Submicron Particle Size Analyzer (Beckman Coulter, Brea, CA).  
Following lyopholization of particles, particles were stored at -20°C.  Zeta potential was 
then measured at 24 hours and then a week after that to assess if there were any changes 
in zeta potential.  These measurements were done on the Delsa Nano Zeta Petential and 




3.4.1 Exposing PLGA microparticles to plasma using an APG system can impart a 
significant change in zeta potential 
Our results indicated that no significant difference exists between the zeta 
potential of particles plasma modified using different dielectric materials (Figure 3.3).  
Previous optimization studies (data not shown) using the APG system suggested that 
although a variety of parameters could be altered during the plasma modification process, 
such as gas flow and applied voltage, the only parameter that altered the zeta potential of 
our microparticles was the frequency with which the voltage was applied (Figure 3.4).  
Therefore frequency of the applied voltage was varied in order to investigate the effects 
of plasma wave generation on surface charge using poly(methylmethacrylate) as the 
dielectric material (Figure 3.4).  We found that treating the PLGA microparticles with 
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helium atmospheric plasma glow (APG) discharge imparted the microparticles with a 
significant negative zeta potential (p<0.01). 
 
3.4.2 Protein loading onto APG modified PLGA microparticles 
As we approached the isoelectric point of ovalbumin (approximately 4.6) we were 
able to achieve the greatest amount of protein adsorption.  The highest concentration of 
protein adsorption was obtained using citrate buffer at a pH of 5.  Under these conditions, 
approximately 36% loading efficiency was observed; meaning the dosage of OVA would 
be 4.3 µg/mg of PLGA (Figure 3.5 and Figure 3.6).   
 
3.4.3 Low pressure plasma exposure causes significant change in zeta potential 
Low pressure plasma was investigated for usage in functionalizing our particles.  
Because the PlasmaTherm offered us the ability to easily investigate different gasses, we 
decided to look at the difference in charge between He plasma modification and O2 
plasma modification.  O2 plasma, aside from introducing different functional groups onto 
the surface of the particles, has also been shown to be more ablative, which may have an 
effect on protein loading.  While, obviously charge is very important in our studies, other 
factors are also involved in protein loading and attachment.  Interestingly, prolonged 
exposure of PLGA to plasma actually demonstrated a loss of some polar groups that had 
been introduced to the surface of the polymer matrix (Wan et al., 2004) which would 
most likely alter the ability to attach protein to the surface (not to mention the increased 
surface roughness would also alter protein adsorption).  Additionally, because plasma is 
known to destroy biologically active materials (Laroussi, 2005) we were interested in 
avoiding prolonged exposure to plasma.  Because He plasma gave a lower zeta potential 
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at a low exposure time (30 seconds) (Figure 3.8) we decided to move forward with the 
remaining protein loading with this exposure time and gas. 
 
3.4.4 Scanning electron microscopy images reveal rougher surfaces on low pressure 
plasma modified particles 
SEM images were taken to provide us with a qualitative prospective of the effects 
of plasma modification on the roughness of our particles.  Figure 3.9 shows fairly 
smooth non-modified PLGA microparticles.  Figure 3.10 and Figure 3.11 both show He 
modified PLGA microparticles.  Here you can see a rougher surface as compared to our 
non-modified microparticles.  Similarly, in O2 modified PLGA microparticles (Figure 
3.12 and Figure 3.13) a rougher surface can be seen.  Because this is a more qualitative 
study, no clear conclusions can be drawn as to whether oxygen or helium plasma is more 
detrimental to our particles.  For that, further studies need to be performed. 
 
3.4.5 Low pressure plasma modified particles can load lysozyme at high efficiency 
Lysozyme, a protein that is cationic at physiological pHs (the isoelectric point is 
11.3), was used as a model protein to test the binding abilities of our anionic 
microparticles.  We showed that we could bind close to 99% in phosphate buffer at a pH 
of 7.  This is significantly higher then what was observed when we attempted to bind 
ovalbumin to our particles (the isoelectric point of ovalbumin is about 4.6).  This 
highlights the importance of surface charge on absorption of proteins.   
 
 47 
3.4.6 Lyopholization does not alter zeta potential of low pressure modified PLGA 
microparticles but the zeta potential is unstable 
For long term usage of plasma modified particles it must be possible to store 
them.  We investigated if lyopholization changed zeta potential (Figure 3.7) and saw no 
significant change in zeta potential after lyopholization.  We then stored the lyophilized 
particles at -20°C for a week and measured the zeta potential of the same batch of 
particles.  Here we saw significant changes in zeta potential (Table 3.1). 
 
3.5 DISCUSSION 
Charged particulate delivery of protein antigens via microparticles is a widely 
researched topic.  As reviewed recently by Leleux and Roy (Leleux and Roy, 2013a) 
particulate carriers are an attractive means for enhancing the delivery of antigens as well 
as increasing the potency of the vaccines themselves.  Here we show a set of studies 
using plasma to modify the charge of PLGA microparticles in order to offer a new 
platform to delivery cationic antigenic proteins.   
Plasma has been investigated for the usage of biomaterial applications in many 
different polymer systems (Morent et al., 2011).  Here we investigated the usage of two 
different plasma systems, an APG plasma system and a low pressure plasma system, to 
modify our PLGA particle systems and, ultimately, load an antigeneic protein on its 
surface.  Plasma modification has been shown to be able to graft proteins as effectively as 
conventional chemical conjugation methods (Huang et al., 2007).  Here, using an 
appropriately charged protein (Figure 3.14), we were able to load close to 99% of the 
model protein antigen, offering a proof of concept that these particles can load proteins at 
high efficiency.  Since PLGA is a biodegradable polymer, less exposure to solutions (like 
the ones that would be necessary to perform a wet chemical conjugation) would be most 
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beneficial in our system.  This could prove to be especially beneficial if we were to 
consider encapsulation within our particle as an additional level of functionality.  
However, we would need to work on minimizing the exposure of our materials to plasma 
as it effectively destroys biological molecules (Eisenbrey et al., 2009; Laroussi, 2005).   
Because we know that plasma may have ablative/destructive effects on the 
surface of our particles we qualitatively investigated the effects of the plasma (Figure 
3.9-3.13).  In the case of PLGA films, increasing the exposure time caused a direct 
increases in the roughness of the surface, and, further, longer treatment times actually 
resulted in less functional groups (as a result of the surface having been destroyed) (Wan 
et al., 2004).  These results were not exclusive to PLGA based systems (Mattioli et al., 
2012).  Obvious changes in roughness of our particles were evident in our images, but, 
again, further analysis needs to be done to make any definitive analysis between 
differences in level of ablativeness between types of plasma. 
Although these results with the APG system were promising, we found that 
overall the data was more unpredictable then we desired.  Specifically, our zeta potential 
measurements often varied from batch to batch with as much as a 20 mV reduction in 
anionic charge.  Although we had assumed this was due to the gradual “wearing out” of 
the dielectric material, literature suggests that APG discharge systems similar to that 
which we are using often produce varied results (Shin and Raja, 2007).  This is attributed 
to instabilities in the discharge itself that ultimately lead to a thermal arc discharge.  The 
transition into a thermal arc discharge can cause a loss of homogeneity of plasma.  
Additionally, because these systems are effectively open to atmospheric air, other gases 
can potentially contaminate the plasma.  Although an APG system holds promise in an 
industrial setting in that it can potentially be scaled up to increase the output of PLGA 
plasma modified particles while  eliminating the expensive equipment associated with 
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more traditional low pressure systems (i.e. cost of vacuum equipment), we decided to 
investigate the usage of low pressure-based systems for our purposes in order to achieve 
more consistent results. 
Another concern with this system is a well-known plasma-associated 
phenomenon, plasma aging.  Plasma treated surfaces are known to go back to their 
original state (i.e. the plasma surface modification is not permanent) (Morent et al., 2010; 
Vesel and Mozetic, 2012).  In short, literature indicates that the longer the polymer was 
treated, the longer the plasma modification lasted.  This is most likely associated with an 
increase in crystallinity at the surface of the material (Vesel and Mozetic, 2012).  We 
have been focusing on shortening the time of exposure to plasma, which may explain the 
very short duration of the plasma’s effects on zeta potential.  These studies confirm the 
results that we observed but were ultimately limited in the conditions tested for storage.  
In conclusion we present here a new way of adding anionic surface charge to 
PLGA microparticles for the delivery of cationic antigeneic proteins.  Because this is a 
dry reaction, it offers the promise of increasing the dosage of any encapsulated agents 













Figure 3.1 Photograph of the atmospheric plasma glow discharge system.  The dielectric 
material covers a parallel plate electrode.  Helium gas is flown through the 
chamber and plasma is generated.  This device was loaned to us by Dr. 
Laxminarayana Raja (Department of Aerospace Engineering, The 




Figure 3.2 An overall schematic of the protein loading experiments for the plasma 
modified particles.  PLGA microparticles are made using a w/o/w emulsion.  
They are then coated onto glass slides at a concentration of 5 mgs/mL.  They 
are exposed to plasma and harvested from the slides.  They are then added to 






Figure 3.3 Altering dielectric materials does not greatly alter the observed zeta potential 
of the microparticles.  The dielectric layer plays an incredibly important role 
by acting to stabilize the plasma formed in this type of system specifically 
by limiting the discharge current and thereby avoiding the arc transition and, 
further, it acts to distribute any randomly formed streamers on the electrode 
surface to form a more homogeneous plasma treatment (as reviewed in 





























Figure 3.4 Changes in the frequency of the applied voltage alters the zeta potential in the 
atmospheric pressure glow discharge system.  Each slide, coated with 2.5 
mgs of PLGA microparticles was exposed to plasma for the same time (6 
minutes) with the same gas flow and same voltage of power.  The particles 























Figure 3.5 Ovalbumin can be loaded onto PLGA microparticles that have been exposed 
to atmospheric glow discharge plasma for 6 minutes at a frequency of 15 
kHz.  Protein was loaded at 1.2 w/w% at 4°C overnight in 10 mM phosphate 
buffer at different pHs.  Protein loading was quantified by measuring the 
non-bound protein using a Micro BCA assay.  We were able to obtain a 24% 
loading efficiency which roughly translates to about 3 µg of ovalbumin per 


























Figure 3.6 Ovalbumin can be loaded onto PLGA microparticles that have been exposed 
to atmospheric glow discharge plasma for 6 minutes at a frequency of 15 
kHz.  Protein was loaded at 1.2 w/w% at 4°C overnight in 10 mM citrate 
buffer.  Protein loading was quantified by measuring the non-bound protein 
using a Micro BCA assay.  Under our best loading condition we were able 
to obtain a 36% loading efficiency which translates to 4.3 µg of ovalbumin 





























Figure 3.7 We investigated the possibility of long-term storage of our particles by 
examining the effects that lyopholization may exert on the zeta potential of 
the particles after plasma modification.  No significant difference in zeta 
potential after lyopholization was seen (as confirmed by analysis using a 





























Figure 3.8:  Here we investigated the effects of using different gasses and different 
exposure times on the zeta potential of our PLGA microparticles using a low 





























Figure 3.9 Scanning electron micrograph image of un-modified PLGA microparticles 




Figure 3.10 Scanning electron micrograph image of low pressure He gas modified PLGA 
microparticles reveals a slightly rougher surface with signs of possible 





Figure 3.11 A closer image of He low-pressure plasma modified PLGA microparticles 





Figure 3.12 Scanning electron micrograph of O2 low-pressure modified PLGA 
microparticles shows evidence of a more ablative process, not only in 
overall surface roughness, but also in actual physical holes created at the 





Figure 3.13 A closer scanning electron micrograph image of O2 low pressure plasma 
treated microparticles reveals a fairly rough surface with clear holes formed 





Figure 3.14 Lysozyme, a protein that is cationic at physiological pH binds very 





























Table 3.1:  Microparticle Surface Relaxes and a significant loss of zeta potential is 
observed over a short period of time. 
Plasma Gas 1 Day 1 Week 
O2 -24.6 -16.0 
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Cationic PEI Modified PLGA Microparticles: Basic Characterization 
for Usage as Protein Based Vaccine   
4.1 INTRODUCTION 
This chapter describes the use of polyethylenimine (PEI) modified PLGA 
microparticles for the development of a protein based vaccine delivery systems.  
Microparticles were synthesized in a water in oil in water (w/o/w) emulsion based 
process and then a simple 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride (EDC) and sulfo N-hydroxysuccinimide (NHS) (EDC/sulfo-NHS) based 
reaction to functionalize the particles with PEI.  Previous work with this system (Singh et 
al., 2008, 2009) focused on encapsulation of immunomodulatory siRNA and surface 
loading of pDNA encoding the protein antigen.  While this is a promising therapeutic 
approach, ultimately vaccines utilizing pDNA for protein production have been 
disappointing in larger primates and humans (as reviewed in (Vajdy et al., 2004)).  Part of 
the limitations of using a pDNA vector to encode for the production of the antigeneic 
protein are, ultimately, the limitations of cellular transfection:  ensuring uptake of here 
pDNA complexes by the DCs, release of the DNA from endocytotic vesicles into the 
cytosol, intracellular routing, transport into the nucleus, and ultimately expression of the 
delivered gene, and, in this case eventual expression onto MHC molecules on the DC.  If 
any of these steps fail, the vaccine will fail to elicit a specific response.  We therefor 
propose using these PEI functionalized microparticles for use in a protein based vaccine.  
Using electrostatic interactions as our driving force, we then electrostatically attached 
ovalbumin (OVA), a model protein antigen, to the surface of the synthesized particles.  
Upon initial in vitro characterization, we saw that protein loaded microparticles alone 
were not sufficient enough to induce strong dendritic cell activation.  Again, using 
 68 
electrostatic interactions, we then attached two known toll-like receptor (TLR) agonists to 
the surface of the PEI-PLGA microparticles:  CpG and siRNA.  Initial dose response 
studies were completed to assess the amount of activation each TLR agonist resulted in.  
Surface loading of multiple molecules was then assessed for further investigation to 
examine the effects of loading our protein antigen and our adjuvant on the same particle 
as compared to separately loaded particles.  This data will be discussed in Chapter 5. 
4.2 BACKGROUND AND MOTIVATION 
Most vaccine formulations function by targeting antigen presenting cells (APCs) 
such as B cells, macrophages and dendritic cells (DCs), which are known to be the most 
prominent T-cell activators.  As discussed in Chapter 2, although DCs have the potential 
to act as a cellular vaccine many limitations exist in using this type of therapy.  Direct 
and highly efficient in vivo delivery of antigens to DCs could overcome the challenges 
associated with ex vivo DC manipulation and may offer a more scalable method for 
generating immunity.   
Bolus injections of purified recombinant proteins or peptides are non-
immunogenic when administered without the addition of an adjuvant and are typically 
subject to degradation and clearance from the body (Bharali et al., 2008).  By utilizing 
recent understandings about the biological nature of how vaccines work to provide long-
lasting T cell priming we can work to rationally design an immune response by 
mimicking the damage signals normally provided by microbial components.  The widely 
used tuberculosis vaccine strain, Mycobacterium bovis BCG, for example, works mainly 
because it contains a number of TLR agonists including:  PG, LAM, lipoproteins, 
lipopetides, and CpG motifs.  A rational combination of appropriate biological cues 
(PAMPs, chemokines, and cytokines) may be appropriate to a pathology and that a 
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combination of these could be used to create an optimal immune response specific to the 
disease (Ehlers and Bulfone-Paus, 2004).  Adjuvants can be used to improve the immune 
response to vaccine antigens in several different ways, and can act by increasing the 
immunogeneicty of antigens, enhancing the speed and duration of the immune response, 
modulating antibody avidity, specificity, isotype, or subclass distribution, stimulating 
CTL, promoting the induction of immunity, enhancing immune responses in 
immunologically immature or senescent individuals, decreasing the dose of antigen in the 
vaccine to reduce costs, and helping to overcome antigen competition in combination 
vaccines (O’Hagan and Singh, 2003; Vajdy et al., 2004).  
One way to both enhance protein uptake by APCs as well as be able to co-deliver 
an immunostimulatory molecule in combination with the protein antigen is by delivering 
them via particulate systems (Singh et al., 2008, 2004a; Vajdy et al., 2004).  As reviewed 
recently by Leleux and Roy (Leleux and Roy, 2013b) particles used for delivery means 
serve a number of important purposes namely in that they help to promote the necessary 
interactions for antigens to be efficiently presented to APCs for both humoral and cellular 
memory by acting in three important ways:  targeting, activation and transfection/antigen 
presentation.  Because particulate delivery systems are more comparable in size to 
common pathogens (~ 1 um) APCs have been shown to preferentially uptake these 
particles and therefore the particle associated proteins as well.  This enhanced uptake by 
APCs is an important contributing factor in the ability of these delivery systems to induce 
more potent immune responses than soluble antigens and, in this way, act as a non-
specific targeting mechanism to APCs.   
Previous work completed by our group focused on using a particulate based 
system to deliver pDNA that encoded the protein antigen along with immunomodulatory 
siRNA specific for IL10 in order to drive a TH1 type immune response (Kasturi et al., 
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2005; Pai Kasturi et al., 2006; Singh et al., 2008, 2009).  Kasturi et al. worked 
extensively on synthesizing and characterizing polyethylene conjugated PLGA 
microparticles showing that his covalent attachment of branched PEI resulted in particles 
that offered not only a cationic surface capable of electrostatically attaching pDNA but 
also buffering capacity that may aid in enhancing phagosomal escape (Kasturi et al., 
2005).  Here we focus on using his non-encapsulated formulation to load protein based 
antigens along with other immunomodulatory molecules by utilizing electrostatic 
interactions.   
The objective of this work present here is to show a rational approach to re-
purposing a microparticle based system capable of inducing in vitro dendritic cell 
activation that will effectively feed into our next set of in vitro and in vivo optimization 
studies.  The general experimental set up (illustrated in Figure 4.1) demonstrates our 
basic design, to use our cationic particles to surface load molecules. 
4.3 MATERIALS AND METHODS: 
4.3.1 Reagents:  
PLGA Resomer® RG502H, ovalbumin (used for characterization studies), 
lysozyme, monosodium phosphate, and disodium phosphate were purchased from Sigma-
Aldrich (St. Louis, MO).  Poly(vinyl alcohol) PVA MW ~ 31,000 was purchased from 
Fluka (Sigma-Aldrich, St. Louis, MO).  On-Targetplus siRNA for IL10 silencing was 
purchased from Thermo Fisher Scientific (Waltham, MA), specifically from their 
Dharmacon subsidiary.  We used CpG sequence 1826 (both non-labeled and FITC-CpG) 
from Invivogen (San Diego, CA).  Micro BCA kit for protein analysis was purchased 
from Thermo Fisher Scientific (Waltham, MA).  Silencer Select Cy3-GAPDH siRNA 
was purchased from Life Technologies, Invitrogen (Austin, TX).  Branched PEI 
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(MW=~70,000 Da) was purchased from Polysciences (Warrington, PA).  1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC) and sulfo N-
hydroxysuccinimide (NHS) were purchased from Pierce Biotechnology (Rockford, IL).  
Antibodies were purchased from eBioscience (San Deigo, CA) except for CD16/CD32 Fc 
Block (BD Pharmingen, San Diego, CA).  Ovalbumin used for dendritic cell activation 
studies was Endograde® Ovalbumin and was purchased through BioVendor (Candler, 
NC).  All other lab items were purchased from Fisher Scientific unless otherwise noted.   
 
4.3.2 Primary Dendritic Cell Isolation and Culture: 
GM-CSF and IL-4 were purchased from Peprotech (Rock Hill, NJ).  Mice were 
purchased from Jackson or Charles River.  Fetal bovine serum was purchased from 
Hyclone, Thermo Fisher Scientific.  Penicillin G with streptomycin was purchased from 
Invitrogen (Austin, TX).  RPMI 1640 was purchased from Sigma Aldrich.  Primary APCs 
will be obtained from bone marrow isolated progenitor cells from Balb/c mice as 
previously described (Inaba et al., 1992).   
Briefly, mice femurs and tibias were be isolated following a protocol approved by 
the University of Texas at Austin Institutional Animal Care and Use Committee 
(IACUC).  The femurs and tibias of the Balb/C mice were isolated, washed with PBS 
and, using scissors, both ends of the bones wereremoved and the marrow isolated by 
flushing out the bone with 2 mL of RPMI 1640 media with a syringe and 25 gauge 
needles.  The collected cells were filtered in order to remove any bone debris.  To 
differentiate the cells into the myeloid lineage, the cells were cultured in RPMI-1640 
medium supplemented with 10% FBS and 20 ng/mL mouse GM-CSF and 20 ng/mL IL-
4.  The media was changed every two days and cells were differentiated for 6-7 days, as 
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recommended, with the intention of removing non-adherent granulocytes.  The 
percentage of DCs was determined by cell surface marker staining (CD11c) and was 
typically seen to be ~80%. 
 
4.3.3 PEI functionalized PLGA Microparticle Synthesis:  
Microparticles were prepared as described by Kasturi et al and Singh et al 
(Kasturi et al., 2005; Pai Kasturi et al., 2006; Singh et al., 2008, 2009) using a water-oil-
water double emulsion/solvent evaporation technique.  Briefly, 0.2 g of PLGA was 
dissolved in 7 mL of dichloromethane (DCM).  300 uL of deionized water was added to 
the polymer solution and immediately homogenized for 2 minutes at 10,000 rpm using a 
Silverson SL2 T homogenizer.  The emulsion was then poured into a 1% PVA (Sigma-
Aldrich, St. Luis, MD) solution and homogenized for 2 minutes and then the DCM was 
evaporated from the solution.  The microparticles were then collected and washed with 
deionized water, lyophilized and stored at -20°C.  
For bPEI conjugation to PLGA particles:  Branched-PEI surface modification of 
PLGA microparticles was completed as described previously (Kasturi et al., 2005; Pai 
Kasturi et al., 2006; Singh et al., 2008, 2009).  Briefly, 40 mgs of PLGA microparticles 
were resuspended in 1.35 mL of cold 0.1M MES (2-(N-morpholino) ethane sulfonic acid) 
buffer (pH 5).  EDC (25 molar excess relative to PLGA) and sulfo-NHS ester (40 molar 
excess relative to PLGA) (Thermo Fisher Scientific Inc, Waltham, MA) was added to the 
PLGA particle suspension for 2 hours at room temperature.  4 molar excess of bPEI (70 
kDa, Polysciences, Washington, PA) was dissolved in 0.2 M MES buffer (pH 6.5) and 
then the pH was adjusted to 8 and reacted with the activated PLGA microparticles for 2 
hours at room temperature.  The PEI conjugated microparticles were then collected and 
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washed 4 times in 1 M NaCl to remove any physically adsorbed PEI and finally once 
with deionized water.  The microparticles were then be lyophilized and stored at -20°C. 
 
4.3.4 Protein and immunomodulatory molecule loading onto PLGA microparticles: 
Protein and other immunomodulatory molecules (CpG ODN 1826 (Invivogen, 
San Diego, CA) and IL10 siRNA (ON-TARGETplus Mouse Il10 siRNA, (Thermo Fisher 
Scientific, Rockford, IL) are loaded onto our microparticles at 1.2% (wt/wt).  Briefly, the 
molecule being loaded were dissolved in phosphate buffer at the pH being tested.  Then, 
PLGA was suspended in the same loading buffer and added; drop wise, to the dilute 
solution in low protein binding tubes.  The protein-PLGA solution was allowed to 
incubate overnight on an end to over shaker at 4°C.  The particles were then harvested via 
centrifugation and the supernatant saved for further analysis using a Micro BCA Protein 
Assay Kit (Thermo Scientific, Rockford, IL) and/or NanoDrop Spectrophotometer for 
single loaded particles.  In the case of dual and triple loaded particles, fluorescently 
labeled immunomodulatory molecules were used.  While some background fluorescence 
was seen between conditions, a standard curve of the second molecule were always run in 
order to subtract off any possible background.  We then subtracted the amount of protein 
or immunemodulatory molecules found in the supernatant from the amount of protein 
initially added to our microparticles to determine the amount of protein bound to the 
microparticle surface.  Initial characterization studies were performed using Ovalbumin 
from Sigma.  Microparticles used for cell studies and in vivo assays were completed with 
EndoGrade Ovalbumin purchased from BioVendor (Candler, NC). 
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4.3.5 Protein release from surface loaded particles: 
After particles were loaded, they were spun down and un-bound protein was 
removed.  These samples were re-suspended and incubated at 37°C and placed on an end-
over-end shaker.  Supernatant was collected at various time points and Micro BCA 
analysis was performed on the samples. 
 
4.3.6 Surface and size characterization of PLGA microparticles: 
Zeta Potential Zeta potential measurement were taken using a Delsa Nano Zeta 
Potential and Submicron Particle Size Analyzer (Beckman Coulter, Brea, CA) and the 
Malvern Zetasizer Nano ZS dynamic light scattering instrument as an indirect estimation 
of surface charge.  The presence of PEI modification will be noted by a positive zeta 
potential as compared to control microparticles.  Zeta sizing was taken on Delsa Nano 
Zeta Potential and Submicron Particle Size Analyzer (Beckman Coulter, Brea, CA).   
 
4.3.7 Dendritic cell in-vitro activation: 
To ensure that DCs are sufficiently activated by  our microparticle formulations 
we stimulated the immature APCs with our microparticle formulation for 48 hours.  
Because we were interested in determining the synergistic effects of our microparticles 
we will investigate the application of a variety of microparticle formulations.  These 
include combinations of:  protein loaded and immunomodulatory loaded microparticles 
as well as microparticles with combinations of both surface loaded proteins as well as 
immunomodulatory molecules.  We  then washed the cells with PBS in order to remove 
microparticles that were not taken up by the APCs.  We will then follow a standard 
FACS staining protocol to stain the cells for appropriate markers.  Briefly, cells will be 
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blocked with anti-mouse CD16/CD32 Fc Block (BD Pharmingen, San Diego, CA) to 
prevent any nonspecific binding.  We   then looked at surface expression of CD11c+ DCs 
of various cell surface markers including CD40, CD86, and CD80.  Flow cytometry 
based analysis will be performed using a BD Accuri flow cytometer and further analysis 
will be performed using FlowJo software.  Cytokine production was also quantified by 
performing ELISA assays monitoring IL12p40, IL12p70, and IL10 at 6, 24, and 48 hours 
using ELISA Ready-Set-Go! kits purchased from eBioscience.  Data was analyzed using 
Microsoft Excel and statistical significance was determined. 
4.4 RESULTS: 
4.4.1 Zeta potential of PLGA microparticles is significantly increased by covalent 
attachment of PEI 
PEI-PLGA microparticles were shown to have a significantly higher zeta potential 
as compared to their non-functionalized counterparts.  This increase was seen at a variety 
of pHs and further, they demonstrated the largest increase at a pH of 5 (Figure 4.2).  In 
KCl solution, PEI-PLGA microparticles typically show a zeta potential of around 
+32.77while non-functionlalized particles have what would be considered a neutral zeta 
potential at -6.29. 
 
4.4.2 Ovalbumin loading on PEI-PLGA microparticles 
OVA was loaded at high efficiency at a pH of 7.  We are capable of achieving a 
10.9 µg of protein per mg of PEI-PLGA microparticles.  We showed that by optimizing 
the protein loading conditions (specifically by altering the pH of the loading buffer) we 
could drive the electrostatic interactions to bind more protein.  We also investigated the 
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usage of citrate buffer (as done in Chapter 3) at lower pHs but found that pH of 7 
produced the most reliable and highest protein loading.   
 
4.4.3 Protein releases quickly from PEI-PLGA microparticles 
We investigated protein release from the PLGA microparticles at 37°C.  Here we 
saw that OVA was released from the particles very quickly, close to 73% was released 
within the first 24 hours (Figure 4.4). 
 
4.4.4 OVA loaded PEI-PLGA microparticles failed to elicit high DC activation 
Because DC activation is of the utmost importance, in order to avoid a 
tollerogenic response to the protein antigen, we were interested in investigating the 
ability of the particles to induce sufficient DC activation.  While an increase in activation 
was demonstrated (Figure 4.5), they were fairly minimal at even higher concentrations.  
In most data, when using endotoxin-free ovalbumin, typically at a 1 µg/mL 
concentration, the PEI-PLGA loaded OVA particles failed to elicit a response that was 
statistically significant from the non-activated DCs. 
 
4.4.5 CpG loading onto PEI-PLGA microparticles 
We were able to loadCpG at high loading efficiency onto the surface of our 
microparticles (Figure 4.6) at lower concentrations (1-2%) but when we attempted to load 
higher concentrations of CpG (5%) we saw a significant decrease in loading efficiency.  
We found that, much like the protein loading experiments, by altering pH of the loading 
particles we could increase loading efficiency, and at a pH of 5.  We were able to more 
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than double our CpG loading capability as compared to the lower dosage we had been 
investigating previously (Figure 4.7). 
 
4.4.6 Higher density of CpG on microparticles does not induce significantly higher 
expression of activation markers on DCs 
We investigated if loading higher quantities of CpG on a microparticle would 
induce higher amounts of activation in DCs.  When comparing the same overall 
concentration of CpG (2 µg/mL) we saw no significant increase in DC activation markers 
between the lower and higher loaded microparticles (Figure 4.8).  When we compared 
conditions based off of the mgs of PEI-PLGA delivered, we did see a slight increase in 
activation marker expression. 
 
4.4.7 Increasing concentrations of TLR agonists increases DC activation surface 
marker expression 
We demonstrated that by increasing, in a step-wise manner, the concentration of 
TLR agonists (Figure 4.9 and Figure 4.10) we saw a similar step-wise increase in cell 
surface marker expression.  Here we see that CpG molecules resulted in a much higher 
increase of activation markers (Figure 4.10) as compared to siRNA (Figure 4.9). 
 
4.4.8 PEI-PLGA micropartcles are capable of loading multiple immunomoedulatory 
molecules 
Next, we investigated our particles’ ability to load multiple immunostimulatory 
molecules in order to ensure that we were delivering multiple molecules to a single cell.  
For dual delivery particles, we focused on OVA, the protein antigen, and CpG (Figure 
4.11).  The dual delivery system was based off of data from section 4.4.7 where CpG 
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resulted in higher amounts of activation, as compared to siRNA.  We then took our work 
further demonstrating that we were capable of loading three stimulatory molecules 
(siRNA, CpG, and protein) onto a single particle (Figure 4.12) at high efficiency.  For 
dual loaded particles, we were capable of binding 11.4 µg of OVA and 11.9 µg of CpG 
onto a single particle.  For the triple loaded particles we demonstrated an ability to load 
10.2 µg of OVA, 9.72 µg of CpG and 9.72 µ of siRNA.  All molecules were loaded at a 
concentration of 1.2 wt% (so for dual particles that’s a total of 2.4 wt% of molecules and 
3.6% for triple loaded particles). 
4.5 DISCUSSION 
Despite significant progress in immunotherapy based research, infectious diseases 
and cancer continue to be a significant world-wide health burden.  New immunization 
strategies need to be employed, however, in order to generate effective immune responses 
to chronic viral or tumor antigens (most of which are self-antigens) as reviewed recently 
by Friede and Aguado (Friede and Aguado, 2005). While many of the most potent 
vaccines on today’s market are given as a live attenuated or killed form of the particulate 
microorganism, there are numerous potential drawbacks for both of these strategies (as 
reviewed in Chapter 2). These include poor efficacy of boosting antibody responses and 
safety concerns.  By applying recent immunological findings such as new information 
about the cells of the immune system and the microenvironments within which these cells 
reside to vaccine development, it may be possible to create a safer, more cost effective 
vaccination. 
In this chapter we presented basic characterization and a rational design for a 
vaccine strategy that we will evaluate further in Chapter 5.  As reviewed in Chapter 2, 
many groups have investigated the usage of charged particles to deliver protein antigens 
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adsorbed onto the surface of particulate based systems.  In doing so, groups have shown a 
high ability to control the amount and disposition of proteins through the use of buffers, 
and have been able to optimize the protein loading process depending on the particulate 
system (Lamalle-Bernard et al., 2006; O’Hagan and Singh, 2003; Singh et al., 2004a, 
2004b).  Here we took our particulate system and systematically altered loading 
conditions to maximize protein loading of our anionic model antigen.  We showed that 
under optimized conditions we were capable of eliciting high amounts of protein loading 
(Figure 4.3).  Further, we showed that the protein releases quickly from our microparticle 
system (Figure 4.4) which may act to prevent some of the deleterious effects observed 
with antigen-depot systems (Hailemichael et al., 2013).  However, the particulate 
delivery system did not induce high amounts of DC activation (Figure 4.5).  For this 
reason we began to investigate combining our protein delivering molecules along with an 
adjuvant.  Initially we focused on using CpG 1826, a commonly used adjuvant (as 
reviewed briefly in Chapter 2).  Particles loaded with CpG induced significantly higher 
amounts of activation (Figure 4.8) on their own and in combination with other particles 
(Figure 4.10).  We further looked to functionalize our system by including siRNA 
specific to IL-10.  Using siRNA for IL-10 has been shown to reduce IL-10 production, 
result in an increase in CD40 expression (after DC activation), and increased Th1 
response in-vitro (Liu et al., 2004).  Further, when siRNA for IL-10 is transfected along 
with another TLR agonist (Poly(I:C)) it acts synergistically with the other adjuvant to 
cause an enhanced Th1 anti-tumor response (Akasaki et al., 2011).  We therefore decided 





Figure 4.1 Schematic representation of PEI protein loading experiments.  PLGA 
microparticles are made using an w/o/w emulsion process.  The PLGA used 
is acid end capped allowing us to use simple EDC/NHS chemistry to 
covalently attach branched PEI to the surface of our particles.  We can 
further functionalize our PEI-PLGA by electostatically attach protein (or 





Figure 4.2 Zeta potential analysis of PEI-PLG and PLGA microparticles in phosphate 
buffer.  Here we investigated the effect of pH on the zeta potential of our 































Figure 4.3 PEI-PLGA microparticles are capable of loading significant amounts of 
ovalbumin:  Ovalbumin was loaded onto microparticles in a dilute solution 
(1.2 w/w%) of PBS (10 mM) at various pHs.  Maximum protein loading was 






























Figure 4.4 Ovalbumin release from PEI-PLGA microparticles at 37°C:  After protein 
loading, particles were incubated on an end-over-end shaker at 37°C to 
assess the amount of protein released from the particles.  Here we see that 
































Figure 4.5 PEI-PLGA microparticles loaded with ovalbumin did not induce high amounts 
of stimulatory surface marker expression on primary DCs:  Because, as 
mentioned previously, activation of DCs is of the utmost importance, we 
assessed whether our particles could induce DC activation.  Here we show 
very little amounts of co-stimulatory marker production, indicating the 


























Figure 4.6 CpG loading onto PEI-PLGA microparticles:  We investigated the loading 
capabilities of PEI-PLGA microparticles to surface load small CpG 
sequences.  We performed these investigations at a pH of 6 (based off of 
previous work loading pDNA onto the surface of PEI-PLGA microparticles 





























Figure 4.7 Altering the pH of the loading buffer enables us to increase the load of CpG on 
the surface of PEI-PLGA microparticles:  By adjusting the pH of the 
phosphate buffer we were able to increase the CpG loading (at 5 w/w%) 
where at optimal conditions the loading was equivalent to approximately 26 
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Figure 4.8 Dendritic cell surface activation marker expression in cells stimulated with 
CpG loaded PEI-PLGA microparticles:  Dendritic cells were activated with 
CpG loaded microparticles and cell surface expression of co-stimulatory 
molecules was assessed.  Although higher densities of CpG did elicit a 
slightly higher expression of stimulatory markers, the increase was not 























2 ug/mL at 1.2 wt% loaded
2 ug/mL at 5 wt% loading
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Figure 4.9 Dendritic cell activation increased by increasing dosage of siRNA for IL10:  
To determine the effects of altering a known TLR agonist, we systematically 
altered the dosage of siRNA loaded microparticles while keeping lower 
dosages of ovalbumin (the model protein antigen) and CpG (a second TLR 
agonist).  We were looking to determine the synergistic effects of the three 
particles delivered.  Here we see that as siRNA loaded particles are 















0.5 ug/mL OVA + 0.5 ug/mL CpG + 0.5 ug/mL IL10
0.5 ug/mL OVA + 0.5 ug/mL CpG + 1 ug/mL IL10
0.5 ug/mL OVA + 0.5 ug/mL CpG + 2 ug/mL IL10
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Figure 4.10 Increasing CpG loaded PEI-PLGA microparticles cause a significant increase 
in activation markers in DCs:  Here, keeping lower dosages of our model 
protein antigen (ovalbumin) loaded PEI-PLGA microparticles and siRNA 
specific for IL10 PEI-PLGA microparticles, we systematically increased the 






















0.5 ug/mL OVA + 0.5 ug/mL CpG + 0.5 ug/mL IL10
0.5 ug/mL OVA + 1 ug/mL CpG + 0.5 ug/mL IL10
0.5 ug/mL OVA + 2 ug/mL CpG + 0.5 ug/mL IL10
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Figure 4.11 PEI-PLGA microparticles are capable of binding both CpG and ovalbumin:  
Here we demonstrate our particles ability to load both CpG and ovalbumin 
in order to co-deliver both an adjuvant particle and a protein on the same 
particle.  Here we used fluorescently labeled CpG (FITC) to simply measure 
fluorescence of the supernatant (i.e. unbound) CpG.  To measure ovalbumin 
loading, similarly, we measured the amount of unbound ovalbumin in the 
supernatant of our samples and calculated from that what was actually 
bound to the particles.  Here, under best conditions, we demonstrated an 

































Figure 4.12 PEI-PLGA microparticles can efficiently load three separate molecules 
(CpG, siRNA for IL10 and a model protein, ovalbumin):  Here we 
demonstrated the ability to load 10.2 µg of ovalbumin, 8.28 µg of siRNA, 
and 9.72 µg of CpG per mg of PEI-PLGA.  CpG and siRNA were quantified 
using fluorescence where we subtracted any background fluorescence 
reading from the other stimulatory molecule.  Protein quantification was 
completed using a micro BCA assay.  All molecules were loaded at 1.2 wt% 
(so in total 3.6 wt% of molecules were added to our PEI-PLGA 
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PEI-PLGA microparticles for in-vitro and in-vivo dendritic cell 
activation towards the rational design of a protein based vaccine 
5.1 INTRODUCTION: 
This chapter explores the usage of the optimized microparticle based system 
investigated in Chapter 4 in both in vitro and in vivo models.  We investigated both 
single and combinatorial loaded microparticles for usage as a platform protein vaccine 
delivery system.  Here we show that we can efficiently activate dendritic cells (DCs) in 
vitro by investigating their surface expression of activation markers as well as cytokine 
secretion of TH1 associated cytokines as well as increases in gene expression in response 
to our particulate formulations.  From these in vitro assays we chose an optimized 
particulate system for further investigations, specifically to study the effects of delivering 
our protein antigen on the same particle as an adjuvant vs. separate delivery.  We next 
studied the effects of our microparticles in vivo in an ovalbumin expressing melanoma 
tumor model where we investigated its potential in both a therapeutic and prophylactic 
model.  Here we showed that our microparticles could reduce tumor growth and 
significantly increased survival.  In our in vivo models, we found that for phophylactic 
studies the dual delivered protein and adjuvant performed statistically better than separate 
protein and adjuvant delivery.  For therapeutic usage, there was no statistically significant 
difference between dual vs. separate delivery. 
5.2 BACKGROUND AND MOTIVATION 
As discussed previously, proteins themselves are very weakly immunogenic and 
when delivered without the addition of an adjuvant incapable of eliciting an immune 
response.  As reviewed recently by Perrie et al (Perrie et al., 2008) there is no standard, 
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general recipe for what makes an effective vaccine, and instead, many criteria exist for 
any given vaccine to function properly.  One of the main concerns is that the vaccine 
generates the appropriate immune response desired against that specific antigen.  As 
discussed in Chapter 2, effective vaccines often include a variety of different immune-
stimulatory molecules that work in combination to achieve the desired effects (Ehlers and 
Bulfone-Paus, 2004).  By focusing on the disease state and understanding the progression 
of the disease, it may be possible to rationally design the desired reaction. 
An imbalance between the TH1 and TH2 response has been implicated in several 
chronic infectious diseases such as human immunodeficiency virus infection and chronic 
hepatitis B and C infections and cancer.  Mature T helper cells, also referred to as CD4+ 
T cells, are central to the induction of anti-viral responses and have been subdivided 
according to two predominant cytokine secretion profiles.  TH1 cells produce cytokines 
such as interleukin (IL)-2, interferon-gamma (IFN-), and tumor necrosis factor beta 
which are important factors responsible for promoting the cell-mediated immune 
response.  TH2 cells produce cytokines such as IL-4, IL-5 and IL-10 which mediate the 
humoral, or antibody mediated response.  Cytokines released by one type of TH 
lymphocyte population can down-regulate the functions of the other TH population 
subset.  Furthermore, it has been suggested that the initial development of APCs into TH1 
or TH2 phenotype is believed to depend on the leading cytokines at the site of initial 
antigen presentation, the type of antigen presenting cell, the nature of the co-stimulatory 
molecules involved, and the dose of stimulatory antigens.  This phenotypic commitment 
may be critical for the subsequent differentiation of immune cells nonspecifically 
recruited at the site of infection (as reviewed in (Thompson, 1995)). 
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By delivering multiple adjuvants using a single particle system it may be possible 
to take advantage of multiple pathways to synergistically control the immune response to 
a given antigen (Hermans et al., 2007; Salvador et al., 2012).   
 
5.3 MATERIALS AND METHODS: 
5.3.1 Reagents 
PLGA Resomer® RG502H, ovalbumin (used for characterization studies), 
lysozyme, monosodium phosphate, and disodium phosphate were purchased from Sigma-
Aldrich (St. Louis, MO).  Poly(vinyl alcohol) PVA MW ~ 31,000 was purchased from 
Fluka (Sigma-Aldrich, St. Louis, MO).  On-Targetplus siRNA for IL10 silencing was 
purchased from Thermo Fisher Scientific (Waltham, MA), specifically from their 
Dharmacon subsidiary.  We used CpG sequence 1826 (both non-labeled and FITC-CpG) 
from Invivogen (San Diego, CA).  Micro BCA kit for protein analysis was purchased 
from Thermo Fisher Scientific (Waltham, MA).  Silencer Select Cy3-GAPDH siRNA 
was purchased from Ambion, Invitrogen (Austin, TX).  Branched PEI (MW=~70,000 
Da) was purchased from Polysciences (Warrington, PA).  1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC) and sulfo N-
hydroxysuccinimide (NHS) were purchased from Pierce Biotechnology (Rockford, IL).  
Antibodies and ELISA Ready-Set-Go!® Elisa kits were purchased from eBioscience 
(San Deigo, CA) except for CD16/CD32 Fc Block (BD Pharmingen, San Diego, CA).  
Ovalbumin used for dendritic cell activation studies was Endograde® Ovalbumin and 
was purchased through BioVendor (Candler, NC).  RNAeasy kit and RT² SYBR® green 
qPCR mastermix was purchased from Qiagen (Hamburg, Germany).  SuperScript® III 
First-Strand Synthesis System was purchased from Invitrogen (Carlsbad, CA).  Primers 
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for RT-PCR for IL12p40, IL12p35, IL10, and house keeping gene mouse β-actin was 
purchased from SABiosciences (Valencia, CA).  All other lab items were purchased from 
Fisher Scientific unless otherwise noted.   
5.3.2 Primary Dendritic Cell Isolation and Culture: 
GM-CSF and IL-4 were purchased from Peprotech (Rock Hill, NJ).  Mice were 
purchased from Jackson or Charles River.  Fetal bovine serum was purchased from 
Hyclone, Thermo Fisher Scientific.  Penicillin G with streptomycin was purchased from 
Invitrogen (Austin, TX).  RPMI 1640 was purchased from Sigma Aldrich.  Primary APCs 
were obtained from bone marrow isolated progenitor cells from Balb/c mice as 
previously described (Inaba et al., 1992).  Briefly, mice femurs and tibias were isolated 
following a protocol approved by the University of Texas at Austin Institutional Animal 
Care and Use Committee.  The femurs and tibias of the Balb/C mice were isolated, 
washed with PBS and, using scissors, both ends of the bones were removed and the 
marrow isolated by flushing out the bone with 2 mL of RPMI 1640 media with a syringe 
and 25 gauge needle.  The collected cells were filtered in order to remove any bone 
debris.  To differentiate the cells into the myeloid lineage, the cells were cultured in 
RPMI-1640 medium supplemented with 10% FBS and 20 ng/mL mouse GM-CSF and 20 
ng/mL IL-4.  The media was changed every two days and cells were differentiated for 6-7 
days, as recommended, with the intention of removing non-adherent granulocytes.  The 
percentage of DCs was determined by cell surface marker staining (CD11c) and was 
typically seen to be ~80%. 
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5.3.3 Synthesis of PLGA microparticles   
Microparticles were prepared as described by Kasturi et al and Singh et al(Kasturi 
et al., 2005; Pai Kasturi et al., 2006; Singh et al., 2008, 2009) and further in Chapter 3 
and 4.  Briefly, PLGA (RG502H, Evonik Rohm GmbH, Essen, Germany) was dissolved 
in dichloromethane (DCM) (Thermo Fischer Scientific Inc., Waltham, MA).  Deionized 
water was added to the polymer solution and immediately homogenized and then the first 
emulsion was poured into a 1% PVA (Sigma-Aldrich, St. Luis, MD) solution and 
homogenized and then the DCM was evaporated from the solution.  The microparticles 
were then collected and washed with deionized water, lyophilized and stored at -20°C.   
 
5.3.4 bPEI conjugation to PLGA particles 
Branched-PEI surface modification of PLGA microparticles was completed as 
described previously (Kasturi et al., 2005; Pai Kasturi et al., 2006; Singh et al., 2008, 
2009) and in detail in Chapter 4.  Briefly, PLGA microparticles were resuspended in 
0.1M MES (2-(N-morpholino) ethane sulfonic acid) buffer (pH 5).  EDC and sulfo-NHS 
ester (Thermo Fisher Scientific Inc, Waltham, MA) was added to the PLGA particle 
suspension for 2 hours at room temperature.  bPEI (70 kDa, Polysciences, Washington, 
PA) was dissolved in 0.2 M MES buffer (pH 6.5) and then the pH was adjusted to 8 and 
reacted with the activated PLGA microparticles for 2 hours at room temperature.  The 
PEI conjugated microparticles were then collected and washed 4 times in 1 M NaCl to 
remove any physically adsorbed PEI and finally once with deionized water.  The 
microparticles were then be lyophilized and stored at -20°C. 
 
 99 
5.3.5 Protein and immunomodulatory molecule loading onto PLGA microparticles 
Protein and other immunomodulatory molecules (CpG ODN 1826 (Invivogen, 
San Diego, CA) and IL10 siRNA (ON-TARGETplus Mouse Il10 siRNA, Thermo 
Scientific, Rockford, IL) were loaded onto our microparticles at 1.2% (wt/wt).  As 
described in Chapter 4, protein was dissolved into the appropriate loading buffer:   PBS 
pH 7 for OVA alone, PBS pH 6 for OVA+CpG, PBS pH 6 for OVA+CpG+siRNA, PBS 
pH 5 for CpG, PBS pH 5 for siRNA.   Then, PLGA was dissolved in the same loading 
buffer and was added; drop wise, to the dilute solution in low protein binding tubes.  The 
protein-PLGA solution was allowed to incubate overnight on an end to over shaker at 
4°C.  The particles were then harvested via centrifugation and the supernatant saved for 
further analysis using a Micro BCA Protein Assay Kit (Thermo Scientific, Rockford, IL) 
and/or NanoDrop Spectrophotometer.  We then subtracted the amount of protein or 
immunemodulatory molecules found in the supernatant from the amount of protein 
initially added to our microparticles to determine the amount of protein bound to the 
microparticle surface.  Initial characterization studies were performed using Ovalbumin 
from Sigma.  Microparticles used for cell studies and in vivo assays were completed with 
EndoGrade Ovalbumin purchased from BioVendor. 
 
5.3.6 Characterization of PLGA microparticles 
Zeta potential measurements were taken using a Delsa Nano Zeta Potential and 
Submicron Particle Size Analyzer (Beckman Coulter, Brea, CA) and the Malvern 
Zetasizer Nano ZS dynamic light scattering instrument as an indirect estimation of 
surface charge.  The presence of PEI modification was noted by a positive zeta potential 
as compared to control microparticles. Zeta sizing was taken on Delsa Nano Zeta 
Potential and Submicron Particle Size Analyzer (Beckman Coulter, Brea, CA).   
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5.3.7 In vitro Characterization 
Primary APCs were obtained from bone marrow isolated progenitor cells from 
Balb/c mice as previously described (Inaba et al., 1992) and previously in section 4.3.2.   
To ensure that our microparticles are sufficiently activated by our microparticle 
formulations we stimulated the immature APCs with our microparticle formulation for 48 
hours.  Because we were interested in determining the synergistic effects of our 
microparticles we investigated the application of a variety of microparticle formulations.  
These included combinations of:  OVA protein loaded and immunomodulatory-molecule 
(CpG and siRNA for IL10) loaded microparticles as well as microparticles with 
combinations of both surface loaded OVA protein as well as immunomodulatory 
molecules (specifically OVA and CpG loaded dual microparticles and OVA, CpG, and 
siRNA triple loaded microparticles).  We then washed our cells with PBS in order to 
remove microparticles that were not taken up by the APCs.  We then followed a standard 
FACS staining protocol to stain our cells for appropriate markers.  Briefly, cells were 
blocked with anti-mouse CD16/CD32 Fc Block (BD Pharmingen, San Diego, CA) to 
prevent any nonspecific binding.  We then looked at surface expression of CD11c+ DCs 
of various cell surface markers including CD40, CD86, and CD80.  Flow cytometry 
based analysis was performed using a BD Accuri flow cytometer and further analysis was 
performed using FlowJo software.  Cytokine production was also quantified by 
performing ELISA assays monitoring IL12p40, IL12p70, and IL10 at 6, 24, and 48 hours 
using ELISA Ready-Set-Go!® Elisa kits purchased from eBioscience.  Briefly, plates 
were prepared and coated with the appropriate capture antibody at 4°C overnight.  Plates 
were washed and standards and samples were incubated for 2 hours at room temperature.  
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After washing, detection antibody was added and incubated at room temperature for an 
additional hour.  Washing was repeated and finally Avidin-HRP was added for detection 
purposes.  Unbound Avidin-HRP was removed via washing and the plate was developed 
using the provided substrate solution and read at 450 nm.  Data was analyzed using 
Microsoft Excel and statistical significance was determined.  RT-PCR was also 
quantified using the same microparticle formulations.  Briefly, RNA was extracted from 
BMDCs using RNAeasy kit (Qiagen, USA).  Complementary DNA (cDNA) was 
synthesized from total RNA using SuperScript® III First-Strand Synthesis System 
(Invitrogen, CA), and real time RT-PCR was performed using RT² SYBR® green qPCR 
mastermix (Qiagen, Germany) on an Applied Biosystem 7900HT Fast real time PCR 
system. Specific primers for mouse IL12p40, IL12p35, IL10, and house keeping gene 
mouse β-actin (SABiosciences, CA) as reference gene were used. Relative gene 
expression level for the target gene were calculated following ΔΔCT method using the 
formula: Target gene expression of sample = 2(−ΔΔCT), where ΔΔCT = [CT (target 
gene) − CT (reference gene)] of treatment − [CT (target gene) − CT (reference gene)] of 
control and the threshold cycle (CT) is the PCR cycle at which first signal of reporter 
fluorescence above a baseline signal is detected. 
 
 
5.3.8 In vivo tumor model challenge:  prophylactic and therapeutic models 
All in vivo studies were performed following a protocol approved by the 
University of Texas at Austin Institutional Animal Care and Use Committee.  Two 
models were investigated in C57BL/6 mice:  a prophylactic model as well as a 
therapeutic model.  For the prophylactic model, briefly, mice were given injections all 
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subcutaneously of the following formulations:  PBS, IFA and Ovalbumin, Ovalbumin 
loaded microparticles, Ovalbumin loaded microparticles with CpG loaded microparticles, 
Ovalbumin and CpG loaded microparticles.  Dosage of all formulations were kept 
constant:  each mouse received a dosage of 50 µg/mouse of OVA and 50 µg/mouse of 
CpG.  A total of three injections were given and on day 30 B16/OVA melanoma cells 
were injected (1*10
5
 cells/mouse).  Tumor growth was measured using a digital caliper 
from Mitutoyo.  When tumors reached critical size (400 mm
3
) or ulcerated mice were 
sacrificed.  In the therapeutic model mice were given an injection of 5*10
5
 cells and then 
injections of microparticle formulations on days 4, 11, and 18.  Again, tumor growth was 
monitored and mice were sacrificed when tumors reached a critical size of 400 mm
3
 or 
when the tumor ulcerated.  Statistical analysis was performed using SPSS software. 
 
5.4 RESULTS 
5.4.1 In vitro characterization and dendritic cell activation 
In order to fully characterize and optimize our particle formulations, extensive in 
vitro studies using primary dendritic cells were performed.  Loading levels of all 
biological molecules were established prior to in vitro characterization studies (Table 1 
and Figure 5.1) and particle dosage was normalized to loading levels for all studies.  All 
results shown are normalized to a concentration of 1 µg of OVA (the model antigen) 
delivered per well (24 well plate at 500,000 cells per well).  Cell surface marker 
expression was analyzed as described (Figure 5.2 and Figure 5.3).  Soluble OVA failed 
to elicit cell surface activation makers and were not significantly different as compared to 
non-activated dendritic cells.  All particulate conditions as well as conditions containing 
CpG (soluble or particle associated) elicited a significant increase in cellular activation 
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markers while soluble siRNA failed to illicit a statistically significant response in surface 
marker expression.  In all conditions, activation was significantly higher when 
immunomoledulatory molecules were delivered using particles as compared to their 
soluble forms.  In most conditions, no significant difference was observed between dual 
loaded particles and triple loaded particles. 
Cytokine secretion by activated dendritic cells was examined at 6, 24, and 48 hour 
time points for IL12p70, IL12p40, and IL10 (Figure 5.5, Figure 5.6, Figure 5.7, and 
Figure 5.8).  IL10 levels in all conditions were extremely low (data not shown).  RtPCR 
was performed in parallel with these studies examining expression of IL12p35, IL12p40, 
and IL10 for correlation purposes (Figure 5.9, Figure 5.10, Figure 5.11, and Figure 
5.12).  In all conditions, IL12p40 cytokine levels (Figure 5.5 and Figure 5.6) were 
significantly higher than IL12p70 levels (Figure 5.7 and Figure 5.8).  Cytokine 
expression levels were highest at 6 hours in most conditions that showed significant 
activation levels.  This trend correlated to RT-PCR data for IL12p35 (Figure 5.9 and 
Figure 5.10) and IL12p40 (Figure 5.11 and Figure 5.12) levels.  Interestingly, while 
there was no statistical difference between LPS activated IL12p40 levels at 6 hours, a 
statistically significant increase was seen as compared to OVA + CpG particles (both 
separately loaded as well as single loaded particle conditions) as time progressed.  
Similar to activation studies, there was no statistical difference in particle conditions 
containing siRNA vs. their OVA+CpG counterpart in separate loaded particles while 
there was a statistically significant difference in the dual vs. triple loaded particles at 48 
hours (not at 24).  IL12p70 levels were, however, significantly higher in LPS activated 
dendritic cells as compared to all conditions at all of the time points examined.  
Interestingly, particles loaded with CpG and OVA separately as compared to single 
particle loaded had significantly higher levels of IL12p70 expression at 6 hours but by 48 
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were no longer significantly higher.  Dual and triple loaded single particle conditions 
behaved similarly.  This may explain why there was little to no difference between dual 
and triple loaded particles in terms of DC activation markers.  Il12p40 levels were not 
statistically different between separately and dual loaded particles in dual as compared to 
triple loaded conditions at 24 hours but at 48 hours, on dual loaded particles IL12p40 
levels were statistically different in dual vs. triple particles.   
 
5.4.2 In vivo tumor suppression 
Tumor suppression was evaluated in both prophylactic and therapeutic models to 
assess the ability of our vaccine system to both prevent as well as treat mice infected with 
an aggressive melanoma tumor.  Vaccine administration and injection schedule was 
based off of previous vaccination models (Li et al., 2011a).  Tumor growth was 
monitored closely and mice were sacrificed based on tumor size as well as signs of 
ulceration.  Statistical analysis was done using SPSS software.  Long rank comparison 
was used to determine statistical significance.  In our prophylactic model (Figure 5.13 
and Figure 5.14), all interventions performed statistically significantly better then PBS 
treated mice alone.  Mice treated with dual and separately loaded microparticles, both 
containing CpG, performed statistically better than mice treated with only Ova loaded 
particles (without the addition of any other adjuvant).  Here we also saw a statistically 
significant difference between separate and dual loaded particles, where the dual loaded 
particles performed better than the separately loaded particles.  Further, there was no 
statistical difference between our dual loaded microparticles and our OVA IFA condition.  
Tumor growth (Figure 5.12) progressed rapidly in PBS control mice where tumors were 
measurable on the ninth day post-tumor cell injection.  In mice receiving microparticles 
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that included CpG in their formulations, tumors were not observed until Day 22, after all 
control mice had already been sacrificed.   
Differences in therapeutic models were similar (Figure 5.15, Figure 5.16, Figure 
5.17, and Figure 5.18).  In the first trial of these studies (Figure 5.15 and Figure 5.16), 
all treatments produced a significant increase in mouse survival.  For our second trial 
(Figure 5.17 and Figure 5.18), particles loaded only with ovalbumin failed to induce a 
significant increase in survival from the untreated.  Further, there failed to be any 
significant difference between the LPS, or CpG and OVA microparticle conditions.  
Whereas in our first trials, both conditions involving OVA antigen along with CpG 
provided a significant increase in mouse survival as compared to our positive LPS OVA 
control.  In both studies, there existed no difference between the separately loaded 
microparticles and the dual loaded microparticle.  One notable difference was the 
surprising delay in tumor growth in the second trial (Figure 5.18).  This delay was 
observed in all conditions and was not a result of treatment.  All mice purchased were the 
same weight (18-20 grams) and were allowed to acclimate to their environment the same 
amount of time (1 week).  Again, when comparing the overall growth curves, you see that 
in the PBS negative control condition, once the tumors began to grow, their growth 
increased very quickly.  In all other treatment cases, tumor growth was greatly delayed; 
this was especially seen in our second trial run.   
 
5.5 DISCUSSION: 
Usage of PLGA for the delivery of vaccine antigens and adjuvants is a widely 
researched field (Milacic et al., 2012) where the administration of PLGA with adsorbed 
or encapsulated antigens has been shown to improve responses in mammals as compared 
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to soluble antigen alone by improving uptake and processing of the antigen.  PLGA 
microparticles can be effectively taken up by immature dendritic cells and does not result 
in maturation of DCs nor does it affect any ultimate functionality of DCs (Waeckerle-
Men et al., 2004).  Here, we took PLGA microparticles, imparted a cationic charge to the 
surface using PEI, a polymer that has been used as an effective non-viral transfection 
reagent, and used that cationic charge to electrostatically attach proteins and 
immunomodulatory molecules onto the surface.   
Our first concern in our particulate system was the ability to induce maturation 
within our dendritic cells in vitro.  To do this, we investigated two different immune 
modulating molecules:  CpG and siRNA.  Where our siRNA was acting not only as a 
potential immune activator (immune response to which is sequence specific (Marques 
and Williams, 2005) but also to actively silence production of a cytokine, IL10, in order 
to drive our TH1 response.  It has been previously shown that dendritic cells that are not 
activated (immature) can not only lead to anergy but actually lead to antigen-specific 
inhibition of preexisting effector T cell function by inducing IL10 production (Dhodapkar 
et al., 2001).  Further, Lutz and Schuler suggest that the existence of a “semi-mature” 
state of DCs that produce CD4+IL10+Treg cells in vivo may induce tolerance (Lutz and 
Schuler, 2002).  So here, we hypothesized that the inclusion of siRNA for IL10 would 
vastly improve our functionality of our microparticle system.  While we did observe an 
increase in activation resulting from inclusion of the siRNA, overall the benefits of 
inclusion of the siRNA in our in vitro analysis was minor.   
Because activation of the DCs was of the utmost importance, and because siRNA 
loaded particles did not induce high amounts of activation (Chapter 4) we also 
investigated the usage of CpG as an adjuvant, which has been extensively investigated for 
protein based vaccines (Davis et al., 1998; Diwan et al., 2002; Malyala et al., 2008; Xie, 
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Hang et al., 2005) and, further, has been investigated in human trials (Halperin et al., 
2003).  While most previously published work focused on encapsulation of CpG, we 
decided to use our PEI functionalized particles to surface load the CpG ensuring 
immediate availability for activation of TLR9 receptors.  We saw a considerable increase 
in activation with our CpG being delivered via our particulate based system, similar to 
what has been observed in other studies (Singh et al., 2001; Xie, Hang et al., 2005).  
When used in combination with a weak antigen, p55gag, Singh et al. showed that using 
antigen loaded cationic PLGA microparticles delivered in combination with CpG loaded 
PLGA particles could elicit a significant CTL response (Singh et al., 2001).  Delivering 
CpG loaded PLGA microparticles along with a protein for an anthrax vaccine resulted in 
a stronger and faster response then AVA alone or AVA in combination with soluble CpG 
(Xie, Hang et al., 2005).  Here we looked to take these studies a step further, combining 
the usage of surface loaded siRNA specific to IL10, CpG and our model protein (OVA). 
In all conditions investigated, activation was increased when immunostimulatory 
molecules were delivered on separate particles.  While it may have been assumed that 
this increase in activation was a result of a larger number of microparticles, non-loaded 
PEI-PLGA microparticles did not induce a significant amount of DC maturation markers 
(as compared to non-activated DCs).  We furthered our in vitro analysis by looking at 
cytokine secretion as well as gene expression.  When we investigated gene expression as 
well as cytokine secretion we saw that, generally speaking, a lack of difference between 
the dual vs. triple loaded formulations when comparing their single vs. multiple loaded 
microparticle formulations.  For this reason, along with cost considerations for ultimate 
end applications, we decided to move forward with our investigations using our dual 
loaded systems.   
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Our in vivo studies were modeled after similar studies completed by other labs 
using other OVA based particulate delivery systems (Li et al., 2011a).  While our studies 
are preliminary, their implications are very interesting.  For our prophylactic model, we 
observed that tumor growth in the PBS control group accelerated quickly and was 
followed closely by our particles containing OVA without any CpG present.  Contrary to 
the general trend observed in our in vitro data, particles loaded with both CpG and OVA 
performed statistically better than the separately loaded particles in a prophylactic model.  
This is contrary to observations seen by other groups (Malyala et al., 2008).  In our 
therapeutic model, this same significance wasn’t seen, though the mice receiving dual 
loaded particles did survive longer.  A second trial indicated the same trend, a lack of 
statistical difference between dual and separately delivered antigen and adjuvant.  These 
results indicate that we have developed a protein based vaccine delivery system capable 
of having significant in vivo effects on tumor growth.  While these studies are promising, 
further work needs to be completed to fully establish, mechanistically, that the vaccine is 
creating a protein-specific response.  Plans for future studies will be further discussed in 
the next chapter (Chapter 6) 
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Table 5.1:  Basic characterization of PEI-PLGA microparticles for protein and 




















Figure 5.2 Scanning electron microscopy image of our PEI-PLGA microparticles:  SEM 
images were taken following the same protocol as discussed in Chapter 3.  







Figure 5.3 Dendritic cell surface activation marker expression in response to dual loaded 
microparticles:  Dendtric cell activation was characterized by examining cell 
surface expression of primary dendritic cells differentiated from bone 
marrow of Balb/c mice for 6-7 days via flow cytometry.  For each 
experimental condition, each well received 1 µg of ovalbumin and cells 
were activated for 48 hours.  Data is representative of multiple independent 
experiments.  For all conditions appropriate soluble controls were performed 
in addition to particulate conditions.  Data shown is surface marker 
expression of only live, CD11c+ dendritic cells (representing approximately 






Figure 5.4  Dendritic cell surface marker expression in response to activation using triple  
loaded microparticles:  Dendtric cell activation was characterized by 
examining cell surface expression of primary dendritic cells differentiated 
from bone marrow of Balb/c mice for 6-7 days.  For each experimental 
condition, each well received 1 µg of ovalbumin and cells were activated for 
48 hours.  Data is representative of multiple independent experiments.  For 
all conditions appropriate soluble controls were performed in addition to 
particulate conditions.  Data shown is surface marker expression of only 
live, CD11c+ dendritic cells (representing approximately 80% of the total 






Figure 5.5 IL12p40 secretion from dendritic cells activated with dual loaded 
microparticles:  Dendritic cells were isolated and cultured in the same 
manner as with previous activation studies.  At 6, 24, and 48 hours after 
addition of particulate formulations and the same dosages used in the 
activation studies, media was removed and cytokine secretion was 





Figure 5.6 IL12p40 secretion from dendritic cells activated with triple loaded 
microparticles:  Dendritic cells were isolated and cultured in the same 
manner as with previous activation studies.  At 6, 24, and 48 hours after 
addition of particulate formulations, media was removed and cytokine 





Figure 5.7 IL12p70 secretion by dendritic cells activated using dual loaded 
microparticles:  Dendritic cells were isolated and cultured in the same 
manner as with previous activation studies.  At 6, 24, and 48 hours after 
addition of particulate formulations, media was removed and cytokine 






Figure 5.8 IL12p70 secretion by dendritic cells activated with triple loaded microparticle 
formulations:  Dendritic cells were isolated and cultured in the same manner 
as with previous activation studies.  At 6, 24, and 48 hours after addition of 
particulate formulations, media was removed and cytokine secretion was 






Figure 5.9 Change in gene expression of IL12p35 in response to dual loaded 
microparticle formulations:  Total RNA was extracted from BMDCs and 
cDNA was synthesized from the RNA using the SuperScript® III First-
Strand Synthesis System (Invitrogen), and real time RT-PCR was performed 
using RT² SYBR® green qPCR mastermix (Qiagen). Relative gene 
expression level for the target gene were calculated following ΔΔCT method 
using the formula: Target gene expression of sample = 2(−ΔΔCT), where 
ΔΔCT = [CT (target gene) − CT (reference gene)] of treatment − [CT (target 
gene) − CT (reference gene)] of control and the threshold cycle (CT) is the 
PCR cycle at which first signal of reporter fluorescence above a baseline 






Figure 5.10 IL12p35 gene expression in triple loaded microparticle activated dendritic 
cells:  Total RNA was extracted from BMDCs and cDNA was synthesized 
from the RNA using the SuperScript® III First-Strand Synthesis System 
(Invitrogen), and real time RT-PCR was performed using RT² SYBR® 
green qPCR mastermix (Qiagen). Relative gene expression level for the 
target gene were calculated following ΔΔCT method using the formula: 
Target gene expression of sample = 2(−ΔΔCT), where ΔΔCT = [CT (target 
gene) − CT (reference gene)] of treatment − [CT (target gene) − CT 
(reference gene)] of control and the threshold cycle (CT) is the PCR cycle at 







Figure 5.11 IL12p40 gene expression in dendritic cells activated by dual loaded 
microparticles:  Total RNA was extracted from BMDCs and cDNA was 
synthesized from the RNA using the SuperScript® III First-Strand Synthesis 
System (Invitrogen), and real time RT-PCR was performed using RT² 
SYBR® green qPCR mastermix (Qiagen). Relative gene expression level 
for the target gene were calculated following ΔΔCT method using the 
formula: Target gene expression of sample = 2(−ΔΔCT), where ΔΔCT = 
[CT (target gene) − CT (reference gene)] of treatment − [CT (target gene) − 
CT (reference gene)] of control and the threshold cycle (CT) is the PCR 


























Figure 5.12 Il12p40 gene expression in triple loaded microparticle formula activated 
dendritic cells:  Total RNA was extracted from BMDCs and cDNA was 
synthesized from the RNA using the SuperScript® III First-Strand Synthesis 
System (Invitrogen), and real time RT-PCR was performed using RT² 
SYBR® green qPCR mastermix (Qiagen). Relative gene expression level 
for the target gene were calculated following ΔΔCT method using the 
formula: Target gene expression of sample = 2(−ΔΔCT), where ΔΔCT = 
[CT (target gene) − CT (reference gene)] of treatment − [CT (target gene) − 
CT (reference gene)] of control and the threshold cycle (CT) is the PCR 































Figure 5.13 B16 OVA expressing melanoma prophylactic model survival curve and 
injection schedule:  Here we show a schematic outline of our injection 
schedule.  Below it is our survival curve of mice in prophalactic model.  
Mice were sacrificed when tumor volume reached over 400 mm
3
 calculated 
using a modified ellipsoidal formula following formula:  tumor volume= ½ 
(length*width
2






Figure 5.14 Prophylactic in vivo model tumor growth curves:  Tumor growth was 
monitored frequently and volume was calculated using the following 
equation:  tumor volume= ½ (length*width
2
) (Euhus et al., 1986; Jensen et 














Figure 5.15 Initial trail for therapeutic vaccination in B16 OVA expressing melanoma:  
Here we show a schematic outline of our injection schedule.  Below it is our 
survival curve of mice in our first trial of our therapeutic treatment study.  
Mice were sacrificed when tumor volume reached over 400 mm3 calculated 
using a modified ellipsoidal formula following formula:  tumor volume= ½ 





Figure 5.16 Tumor volume growth in first trial of therapeutic model for ovalbumin 
expressing melanoma:  Tumor growth was monitored frequently and volume 
was calculated using the following equation:  tumor volume= ½ 
(length*width
2
) (Euhus et al., 1986; Jensen et al., 2008; Tomayko and 




Figure 5.17 Second trial of therapeutic vaccine use for B16 melanoma model:  Following 
the same injection schedule as before, here we show our survival curve of 
mice in our first trial of our therapeutic treatment study.  Mice were 
sacrificed when tumor volume reached over 400 mm
3
 calculated using a 
modified ellipsoidal formula following formula:  tumor volume= ½ 
(length*width
2







Figure 5.18 Tumor volume growth in second trial in therapeutic treatment model for B16 
melanoma tumor:  Tumor growth was monitored frequently and volume was 
calculated using the following equation:  tumor volume= ½ (length*width
2
) 
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Conclusion and Future Directions 
6.1 SUMMARY: 
We have demonstrated the applicability of using charged microparticle systems 
for protein antigen delivery along with adjuvant immune modulating molecules for the 
potential usage as a platform vaccine system.  The cationic protein loaded particles have 
demonstrated, when delivered in combination with adjuvant molecules, that they are able 
to illicit dendritic cell activation in vitro as well as offer some protective as well as 
therapeutic effects in vivo in our ovalbumin expressing melanoma model.  For our 
anionic protein delivery system, we have completed a set of preliminary studies 
indicating that our dry functionalization method (plasma surface modification) can 
enhance the anionic property of the surface of PLGA microparticles and can offer an 
effective substrate for the electrostatic attachment of cationic proteins.  Our results 
indicate two promising systems for the delivery of protein adjuvants. 
 
 6.1.1 CONCLUSIONS ON OUR PLASMA MODIFIED PLGA MICROPARTICLE BASED 
ANTIGEN DELIVERY SYSTEM 
Plasma modification techniques have been widely used to develop a more 
bioactive or biocompatible surface in many different applications (Alves et al., 2007, 
2008; Armentano et al., 2009; Bélard et al., 2013; Desmet et al., 2009; Hasirci et al., 
2010).  Here we demonstrated usage in a microparticle based system where the particles 
were modified by coating on a glass cover slide and being exposed to plasma.  In the 
literature, this type of application of plasma modification has yet to be reported (most 
work focuses on either modification of the polymers themselves or of polymer based 
films).  We showed, that for our purposes, we were able to impart a change in surface 
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functionality as indicated by a clear shift in zeta potential of our particles.  We 
investigated a number of different plasma types (atmospheric and low pressure), gases 
(helium and oxygen), as well as other modulatory factors according to plasma source in 
order to optimize our system.  While experiments were in process, we began to observe 
sudden shifts in zeta potential from our atmospheric glow discharge system.  Specifically, 
we were observing high run-to-run variability in the observed zeta potentials.  The 
differences noticed could most likely be a result of an inherent flaw in the system 
discussed by Shin and Raja where shorter plasma modification times  result in a 
difference in voltage-current waveforms at the start of each new run (Shin and Raja, 
2007).  While this wouldn’t matter for longer plasma exposure, it does matter for our 
purposes since we need to minimize the ablative effects of longer exposure times on our 
microparticles (Wan et al., 2004).   
We next began investigating the usage of low-pressure based systems.  The 
observed results were highly consistent (as compared to the atmospheric system).  
Further, we were able to load lysozyme at very high efficiencies (over 98% at a 1.2 wt% 
loading).  SEM images revealed what appeared to be slightly rougher surfaces of the 
plasma modified particles.  We next investigated surface aging (Morent et al., 2007; 
Vesel and Mozetic, 2012).  In our particles, we observed significant decreases in zeta 
potential of our particles in short periods of time.  Similarly, Morent et al. observed 
drastic changes in surface properties within the first 48 hours of storage of polypropylene 
and polyethylene terephthalate films.  Their studies suggested that the choice of gas 
during plasma modification played a key role in the effects of aging.  Specifically, they 
suggested that the more cross-linked the surface of the polymer film was, the more likely 
able it was to resist the effects of aging (Morent et al., 2007).   While this could provide 
stability of the charge on the surface of the particles, it would limit the diffusion of 
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material out of the particles should we move forward with encapsulation of another agent 
within the particles.  We have primarily focused on creating a balance between the charge 
of the particle while limiting the exposure time of the particles to plasma, not only to 
limit the degradative effects of plasma, but also to keep open the option of encapsulation 
of a bioactive agent within the particles (Eisenbrey et al., 2009; Holy et al., 2001).   
 
6.1.2 CONCLUSIONS ON OUR PEI MODIFIED PLGA MICROPARTICLE BASED ANTIGEN 
DELIVERY SYSTEM 
We have shown that by covalently conjugating branched polyethyenemine we can 
significantly increase the zeta potential of PLGA microparticles.  Using this cationic 
charge, we can alter loading conditions (we did this by altering the type of buffer and 
their respective pHs) to drive electrostatic interactions and increase the ability of the 
particles to adsorb proteins (Chapter 4).  With the inclusion of immunomodulatory 
molecules, we can increase the activation of primary dendritic cells.  Different 
combinations of antigenic protein and immunomodulatory molecules (CpG and siRNA 
for IL10) resulted in different expression profiles of primary DC activation markers as 
well as secretion of cytokines and gene expression.   
We also investigated the difference between delivering our protein antigen in 
combination with our immunomodulatory molecules on the same particle vs. separate 
particles (Chapter 5).  Generally speaking, we found that triple loaded particles (CpG, 
siRNA, and OVA) as compared to our dual loaded particles (CpG and OVA) did not 
increase in vitro DC activation enough to warrant the cost of in vivo investigation.  
Therefore, for our purposes, we continued our investigations with only our dual loaded 
particles and their single particle controls.  Our preliminary studies indicate that as a 
prophylactic vaccine, our particles can provide a significant amount of protection and that 
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the dual loaded particles produce the highest statistically significant increase in 
protection.  Our therapeutic trial results were not as definitive.  Here we observed that the 
dual vs. separate particles did not perform statistically different in vivo (nor did either 
particulate system perform better than our positive control, IFA and OVA).  
As suggested by Kasturi et al. (Kasturi et al., 2011) the ability to deliver antigens 
and adjuvants on separate particles offers an interesting new platform for coupling a 
generic adjuvant particle with another particle containing an antigen from a different 
pathogen.  This separately functional adjuvant loaded particle could act, not only in an 
antigen sparing way but could also, ultimately reduce the number of vaccinations a 
person needs to receive (i.e. it may be possible to receive a vaccination against multiple 
antigens at the same time, assuming the type of immune response desired is the same). 
 
6.1.3 RECOMMENDATIONS FOR FUTURE WORK 
Currently, we have investigated usage of two differently charged particle systems 
based upon using PLGA microparticles and then altering their surface functionality to 
electrostatically attach protein antigens to their surfaces.  We have focused exclusively on 
electrostatics to surface load molecules onto our particles in our investigations.  If our 
anionic plasma modified particles behave similarly to our PEI-PLGA microparticles, an 
adjuvant may be necessary to elicit an immune response.  As previously suggested in 
6.1.1 there are a number of concerns that would need to be addressed with this.  First and 
foremost we would need to establish that any encapsulated agent remains bioactive after 
plasma surface modification.  Depending on the adjuvant/immunomodulatory molecule 
used this can be done easily in a number of ways.  If we continue using an siRNA 
molecule, a GAPDH siRNA can be used as a model siRNA, extracted after exposure to 
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plasma, and a KDalert™ Assay can be performed.  Similarly we could test the 
functionality of other active molecules on their effects on primary immune cells (i.e. 
compare non-plasma exposed molecules to exposed molecules).  As suggested in section 
6.1.2, if having our adjuvant on the same molecule vs. separate molecules does not affect 
ultimate functionality in vivo of the system, alternatively, it may be possible to use both 
our plasma modified particles (loaded with protein antigen) and our cationic particles 
(loaded with adjuvant) in combination with one another.   
The aging of the surface of our plasma modified microparticles is also an issue 
that needs to be addressed.  Obviously, this is a well-documented phenomenon, but 
attempts to prevent it have met with limited success.  Most aging studies occur in less 
than ideal storage conditions (Li et al., 2003; Morent et al., 2007; Vesel, 2010).  It has 
already been established that, at least in the case of helium plasma treatment, the surface 
actually reacts with the environment to gain its new functional groups.  We have shown 
(Chapter 3) that lyophilization overnight does not change the zeta potential of our 
particles.  Perhaps limiting the interaction of the microparticles with air would prevent 
some of this surface relaxation.  Further, as with most reactions, temperature can play a 
very important kinematic role.  Therefor there may be several different storage conditions 
we could evaluate to reduce the effects of aging.  Further, we may stabilize the functional 
groups by actually loading our protein antigens onto the surface of the particles 
immediately and storing them pre-loaded.  This would reduce some of the functionality 
of the vaccine system in that they would have to be pre-loaded with antigen, would still 
be a satisfactory alternative if the particles are not stable in conditions that would be 
favorable for long-term storage.  
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Once these two topics have been investigated, we could begin studying the 
therapeutic effects of these particles with cationic proteins in vivo to elucidate their 
effectiveness in an appropriate model.   
In vivo trials of our particulate formulations have only just begun.  As mentioned 
previously, our prophylactic study has only been completed a single time, and thus, needs 
to be repeated to confirm our initial findings.  Further, additional groups need to be 
investigated within our system.  Specifically, we need to evaluate the effects of CpG 
microparticles alone on tumor protection.  It has been demonstrated that CpG alone can 
have a therapeutic effect when delivered without a protein antigen (Heckelsmiller et al., 
2002; Kigasawa et al., 2011).  We therefore would need to both test the effects that CpG 
microparticles alone have on our system as well as investigate the specificity of the 
immune response that we have generated.  One way to do this would be to perform an in 
vivo cytotoxic T-cell assay (Cui and Qiu, 2006; Li et al., 2011b).  Briefly, this would 
involve vaccinating mice with our formulations and then introducing splenocytes from 
naïve mice that have been pulsed with OVA as well as labeled with CFSE.  In this way it 
would be possible to determine if our results were specific to cells producing the protein 
antigen or if it was a direct result of the CpG alone. 
One of the main criticisms on this project was the choice of animal model for our 
studies.  The B16-OVA expressing melanoma cells were designed to study the anti-tumor 
effects of molecules while expressing OVA as an antigen (Brown et al., 2001).  To say 
the least, this kind of tumor is an optimal one to study in that it has high expression of the 
antigen on its surface.  This is not usually the case, and in fact tumor cells can actually 
down regulate their MHC expression to avoid detection (as reviewed in (Algarra et al., 
2004)).  To fully establish our microparticle based vaccine’s functionality, it would be 
better to test it in a more realistic tumor model with an actual tumor protein antigen.  
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Further, to show our particles’ platform functionality, it may be useful to investigate its 
application to other disease models. We know that the hepatitis b surface antigen’s 
isoelectric point is very close to that of ovalbumin’s so transitioning into that disease 
model should be fairly simple.  We conclude that given our past studies and planned 
studies we have an effective prototype set of particles that may be used in a safe, 
synthetically based vaccine system. 
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